



FEBS Letters

journal homepage: www.FEBSLetters.org



Review

A *Drosophila*-centric view of protein tyrosine phosphatases



Teri Hatzihristidis^{a,b}, Nikita Desai^{a,c}, Andrew P. Hutchins^d, Tzu-Ching Meng^{e,f,g},
Michel L. Tremblay^{a,b,c,*}, Diego Miranda-Saavedra^{h,i,j,*}

^a Goodman Cancer Research Centre, McGill University, 1160 Pine Avenue, Montreal, Québec H3A 1A3, Canada

^b Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada

^c Department of Biochemistry, McGill University, Montreal, Quebec, Canada

^d Key Laboratory of Regenerative Biology and Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong 510530, China

^e Taiwan International Graduate Program, Academia Sinica, Taipei, Taiwan

^f Institute of Biochemical Sciences, National Taiwan University, Taipei, Taiwan

^g Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan

^h World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, 3-1 Yamadaoka, Suita 565-0871, Osaka, Japan

ⁱ Centro de Biología Molecular Severo Ochoa, CSIC/Universidad Autónoma de Madrid, 28049 Madrid, Spain

^j IE Business School, IE University, María de Molina 31 bis, 28006 Madrid, Spain

ARTICLE INFO

Article history:

Received 16 February 2015

Revised 2 March 2015

Accepted 2 March 2015

Available online 13 March 2015

Edited by Ivan Sadowski

Keywords:

Tyrosine phosphatase

Sequence analysis

PTP-central

Model system

Phosphorylation

Biochemical evolution

Drosophila

ABSTRACT

Most of our knowledge on protein tyrosine phosphatases (PTPs) is derived from human pathologies and mouse knockout models. These models largely correlate well with human disease phenotypes, but can be ambiguous due to compensatory mechanisms introduced by paralogous genes. Here we present the analysis of the PTP complement of the fruit fly and the complementary view that PTP studies in *Drosophila* will accelerate our understanding of PTPs in physiological and pathological conditions. With only 44 PTP genes, *Drosophila* represents a streamlined version of the human complement. Our integrated analysis places the *Drosophila* PTPs into evolutionary and functional contexts, thereby providing a platform for the exploitation of the fly for PTP research and the transfer of knowledge onto other model systems.

© 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

1. Introduction

Reversible protein phosphorylation is one of the most widespread mechanisms for controlling cellular functions. Tyrosine phosphorylation, in particular, has evolved into a sophisticated regulatory system in metazoans to control many animal-specific processes, ranging from development to cellular shape and

motility, transcriptional regulation and proliferation versus differentiation decisions [1]. Out of 498 genes encoding protein kinases in the human genome, 91 encode tyrosine kinases (TKs) [2]. The set of TKs is complemented with 109 protein tyrosine phosphatase (PTP) genes [3], although TKs and PTPs do not seem to have overlapping targets.

Given the central importance of tyrosine phosphorylation, it is no surprise that its abnormal regulation is responsible for many human diseases: diabetes, obesity, cancer, inflammatory diseases, and many others have been associated with PTP over-expression or deficiencies in human [4]. Historically research on TKs has advanced at a faster rate than that on PTPs; not only were TKs identified nearly a decade earlier than PTPs, but also the intrinsic difficulties of investigating the “disappearance” of a phosphate moiety as opposed to the appearance of a radioactive phosphate represented a major burden for the PTP field. Major advances have

Author contributions: TH, ND, APH and TCM analysed data and wrote the manuscript. MLT and DMS conceived and supervised the study, analysed data, and wrote the manuscript.

* Corresponding authors at: Goodman Cancer Research Centre, McGill University, 1160 Pine Avenue, Montreal, Québec H3A 1A3, Canada (M.L. Tremblay). World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, 3-1 Yamadaoka, Suita 565-0871, Osaka, Japan (D. Miranda-Saavedra).

E-mail addresses: michel.tremblay@mcgill.ca (M.L. Tremblay), diego@ifrec.osaka-u.ac.jp (D. Miranda-Saavedra).

<http://dx.doi.org/10.1016/j.febslet.2015.03.005>

0014-5793/© 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

been made with the development of substrate trapping techniques where specific mutations of the PTP catalytic domains allow the purification, detection and identification of their physiological substrates. Although PTPs are generally expressed at low levels, they are enzymatically very active and as a result their ectopic expression in cellular systems easily leads to off-target effects, usually resulting in cell death [5]. Therefore, the use of model organisms is indispensable for the study of PTPs.

Today we know that in most cases phosphatases play a dominant role over protein kinases in shaping the spatio-temporal dynamics of protein phosphorylation networks, which are characterized by their amplitude and duration [6]. Thus it has been proposed that in many instances protein phosphatases make better drug targets than protein kinases. Most of our current knowledge on PTPs is derived from mutations identified in human pathologies as well as loss-of-function studies in the mouse (embryonic gene targeting models, and siRNA and shRNA knockdown experiments). To a large extent, the murine genetic deletions correlate well with human disease phenotypes and have been instrumental in understanding the central importance of PTPs in cellular signaling, whose effects can range from embryonic-lethal to relatively mild and nearly unnoticeable likely due to the presence of compensatory mechanisms by paralogous PTP genes [4,5]. Whereas the mouse has so far been the favoured organism for the genetic dissection of PTP-controlled pathways, here we argue that *Drosophila melanogaster* with its streamlined version of the human tyrosine phosphatome is a complementary and powerful system for the dissection of PTP functions in vivo.

The fruit fly occupies a paramount position among model organisms: *Drosophila* research yielded the first observations on a wide variety of fundamental biological principles that are conserved in humans despite several hundred million years of independent evolution [7–9]. These include the principles of embryonic patterning by Hox genes, which apply to all bilaterian animals [10], and the functional conservation of other key signaling pathways, including among others: (i) the Notch signaling pathway [11–22]; (ii) the Wnt set of signal transduction pathways, which function in various developmental pathways (body-axis patterning, cell migration, cell fate specification, cell proliferation; and (iii) the identification of the *Drosophila* receptor tyrosine kinase gene *Sevenless* (*sev*), whose target protein Son of sevenless (*Sos*) unveiled the relationship between receptor TK and Ras signaling in eye development [23]. These conserved signaling pathways are frequently dysregulated in cancers and type II diabetes [24–27].

The main advantage of the fly over other model organisms is that once a suitable phenotype has been obtained, its genetic toolkit can be used to dissect the underlying disease pathways either by loss-of-function (by RNAi, transposon insertion, imprecise excision, or X-ray and chemical mutagenesis [28]) or gain-of-function in a tissue-specific manner (e.g. using the GAL4/UAS system [29]). Thus, *Drosophila* is a particularly attractive system for establishing models of human disease and studying genetic interactions for a number of reasons [8]: (i) many well-studied biological pathways are conserved between human and *Drosophila*, including pattern formation, endocrine and intracellular signaling, and cell death [30]. Furthermore, in recent times the fruit fly has emerged as an extraordinarily powerful model for the study of human metabolism, where a homolog of leptin (a hormone that regulates energy intake and expenditure, including appetite, hunger, metabolism and behavior) called *unpaired 2* (*upd2*, a JAK-STAT pathway ligand) works similarly to human leptin [31]; (ii) over 75% of human disease-associated genes have a homolog in the fly [32], and as such fly models have been successfully established for many distinct diseases, including neurodegenerative disorders, cancer, cardiac, immunological and developmental

disorders [33]; (iii) its short life cycle and abundant progeny facilitates genetic modeling, whereas its relatively short lifespan (~120 days) makes studies on ageing particularly feasible.

Here we describe the PTP complement of *D. melanogaster*, a model organism where studies on tyrosine phosphatases have previously shed light on key pan-metazoan functions. We draw similarities and differences between the tyrosine phosphatome of the fruit fly and those of human, mouse, worm and yeast, highlighting important conserved functions that underline the potential of the fruit fly as a key model organism for the genetic and biochemical study of tyrosine phosphatases in higher animals.

2. A revised annotation of the *Drosophila* tyrosine phosphatome

The PTP superfamily is divided into 4 distinct classes that differ both in their catalytic mechanisms and phosphatase catalytic domain sequences [34]. **Class I** are cysteine-based PTPs including the classical tyrosine-specific phosphatases (both receptor and non-receptor), and the dual-specificity phosphatases (DSP, or VH1-like). DSPs are the most promiscuous type of PTPs in terms of substrate specificity, with some members dephosphorylating mRNA 5'-triphosphate while other enzymes dephosphorylate lipids. **Class II PTPs** are a small but evolutionarily highly conserved group of PTPs with only one member in humans (ACP1); they are also found in bacteria (which display tyrosine phosphorylation [35]) and are structurally related to bacterial arsenate reductases. **Class III PTPs**, like the Class I and II, are also cysteine-based enzymes displaying specificity towards tyrosine and threonine residues. The human enzymes (CDC25A, CDC25B and CDC25C) control cell cycle progression by dephosphorylating cyclin-dependent kinases. Despite sharing a cysteine-based catalytic mechanism, Class I, II, and III PTPs are believed to have evolved independently. A fourth class of PTPs displays an aspartic acid-based catalytic mechanism with dependence on a cation, and is represented by the developmentally important *EyA* ('Eyes Absent') genes, of which only one member is found in the fruit fly compared to four genes in mouse and human.

We recently developed a highly sensitive and specific method for the automatic classification of proteins into the various PTP classes and families ('Y-Phosphatomer'). Y-Phosphatomer relies on a specific collection of protein domain models drawn from InterPro member databases [3]. Upon evaluation, Y-Phosphatomer reported perfect coverage and classification rates. Then, as proof of principle we reannotated the human tyrosine phosphatome and showed that the human genome harbors 109 PTP genes instead of 105 genes as originally reported in a landmark paper 10 years ago [34]. We subsequently used Y-Phosphatomer to annotate the PTP complements of 65 eukaryotic genomes (including *Drosophila*), which are available through the PTP-central database (<http://www.PTP-central.org/>) [3]. The *D. melanogaster* genome contains 44 PTP genes (Fig. 1A), with RNA-seq data from FlyBase [36] supporting both the robust expression and intron-exon structures of all PTPs genes. The curated tyrosine phosphatome of the fly presented here extends the previous catalogue of 16 (classical) tyrosine-specific PTPs [37] by 21 dual-specificity phosphatases (DSPs), 4 Class II phosphatases (LMWPs), 2 Class III phosphatases (CDC25s) and 1 eyes-absent (*EyA*) homolog (Table 1).

Previous efforts at characterizing the PTP complement of *D. melanogaster* include those by Andersen et al. [37] and Morrison et al. [38]. While the former study exclusively concentrates on Class I tyrosine-specific PTPs (and correctly identifies all 16 genes in *Drosophila*), the latter is much broader in scope and attempts to identify all protein kinases and phosphatases in the fly genome. To do so, Morrison and colleagues mined the fly genome using




Fig. 1. (A) The PTP gene complement of various model organisms, from Dictyostelium to human. The figures reported here constitute the automatic predictions in the PTP-central database [3], which have been manually annotated for human and *Drosophila*. (B) Histograms displaying the contribution of each PTP class to each species' tyrosine phosphatome. Most of the enlarged repertoire of PTPs in the worm are tyrosine-specific PTPs, whereas in *Drosophila* and vertebrates DSPs make up as much as half of the organism's PTP complement. N.B. The various PTP families are described in detail in Table 1.

BLAST [39]. An exhaustive analysis of the dataset by Morrison et al. [38] showed that the authors identified only ~80% (36/44) of the fly's PTPs, many of which were either incorrectly annotated or at the time only represented as fragmentary sequences in the *Drosophila* genome. This emphasizes the superiority of protein family-specific profile hidden Markov model (HMM) methods over general tools such as BLAST for the database search and automatic classification of proteins into families. Carefully curated HMM

collections are both especially sensitive and specific, as we previously demonstrated for protein kinases [2,40] and ubiquitinating and deubiquitinating enzymes [41]. The protein models combined into the Y-Phosphatome library were specifically built to represent the diversity of the PTP repertoire and Y-Phosphatome outperforms search efforts that use standard sequence-analysis tools.

3. The *Drosophila* tyrosine phosphatome is a streamlined version of the human complement

The *D. melanogaster* genome contains 44 PTP genes (Table 1, Fig. 1A). All phylogenetic relationships reported here are those available on the PTP-central site, and as originally fetched from the MetaPhOrs database [42]. MetaPhOrs is a public repository of orthologs and paralogs derived from phylogenetic trees from five distinct databases (PhylomeDB [43], Ensembl [44], EggNOG [45], Hogenom [46] and TreeFAM [47]). Thus, MetaPhOrs is the most comprehensive database of homology relationships currently available, and provides specific metrics to assess the quality of the PTP homology predictions reported here.

Interrogation of the PTP complements of other model organisms in PTP-central shows that the proportion of genes encoding PTPs is kept in strict bounds from yeast to human (~0.2% of all genes). The fly's PTP complement is larger than that of yeast (17 genes), but smaller than those of *C. elegans* (125 genes) or human (109 genes) (Table 1, Fig. 1). The *C. elegans* genome, however, is known to have undergone large protein family expansions in comparison with other nematodes of similar phenotypic complexity [48], including 11 receptor PTPs harboring unique extracellular domains that are absent in other species [49].

Whereas 75% of human PTPs are multidomain proteins [34], only about half of the fly PTPs harbor accessory domains that enhance the enzymes' capabilities. In striking contrast, some serine/threonine phosphatases, such as PP1, mainly consist of small catalytic subunits that bind regulatory or targeting subunits to form holoenzymes with different functions. PP1 Ser/Thr phosphatases may in principle generate more flexibility and functional diversity, but strict specificity must be provided by the PP1-interacting proteins that serve as targeting subunits, substrates and/or inhibitors [50]. Hence one may argue that the tight regulation typical of single-chain multidomain PTPs may be better suited to the specific regulation of signaling pathways. We describe 17 accessory domains associated with the fly PTPs, which can be classified into four main functional categories: (i) cellular localization (e.g. FERM and PH); (ii) protein–protein interaction (e.g. SH2, immunoglobulin); (iii) catalytic (e.g. the catalytic domain of mRNA-capping enzyme); and (iv) small-molecule binding (e.g.

Table 1

Comparison of the human and *Drosophila* tyrosine phosphatomes split by PTP class and family.

PTP classification			Human	Fruit fly
Class I	Classical PTPs Classical PTPs Dual-specificity PTPs	Receptor PTPs	20	8
		Non-receptor PTPs	20	8
		MKP	11	2
		Atypical	19	8
		Slingshots	3	1
		PRL	3	1
		CDC14	4	1
		PTEN	5	1
		Myotubularins	16	7
		LMWP	1	4
Class II	LMWP	LMWP	1	4
		CDC25	3	2
Class III	CDC25	CDC25	3	2
		EYA	4	1
Asp-based PTPs	EYA	4	1	
Total			109	44




Fig. 2. Protein domain architectures of *Drosophila* PTPs. We describe 17 accessory domains in association with the fly's PTPs. Accessory domains impart additional functions, which can be classified into four functional categories: cellular localization, protein–protein interaction, catalytic and small-molecule binding. Although comparatively more human PTPs harbor accessory domains, the types of such domains found both in human and fly PTPs are almost identical.

C1) (Fig. 2). It must be noted, however, that although comparatively more human PTPs harbor accessory domains, the types of accessory domains found in both human and fly are almost identical.

3.1. *Drosophila* pseudophosphatases

Besides regulation by accessory domains and interacting proteins, PTPs that lack catalytic activity ('pseudophosphatases') provide an additional level of complexity. Proposed functions of pseudophosphatases include: (i) being part of scaffolding signaling complexes; (ii) acting as 'antiphosphatases' that protect specific substrates from other active PTPs; and (iii) working as functional inhibitors of their substrates to stoichiometrically remove phosphorylated proteins from their normal signaling functions, as has been suggested for the *C. elegans* pseudophosphatases EGG-4 and EGG-5 [51,52].

The importance of catalytically inactive enzymes in regulating key cellular processes was probably first understood in the case of pseudokinases, which act as signal transducers by integrating signaling network components, as well as being allosteric activators of active protein kinases [53,54]. In *Drosophila*, 11/44 (25%) of PTPs harbor catalytically inactive domains (labeled 'PTPI' in Fig. 2), including 4 receptor (Lar, Ptp69D, Ptp99A and IA-2) and 2 non-receptor PTPs (CG7180 and Mop), 3 myotubularins (CG5026, CG14411 and Sbf), and 2 LMWPs (Primo-1 and CG31469). The classification of a PTP as a pseudophosphatase is not as straightforward as it is for protein kinases: a kinase should lack at least one of three essential motifs in the catalytic domain (the VAIK, HRD or the DFG motif) to be classified as a pseudokinase [53]. In 2001, Andersen et al. [55] described 10 conserved motifs in

the catalytic domain of PTP1B and highlighted specific amino acids common to all PTPs that play critical roles in catalysis. We used both information from the literature and this set of sequence conservation criteria to predict the catalytic activity of *Drosophila* PTPs. For instance, the second domains (D2) of all receptor PTPs lack a critical amino acid in motif I (Tyr46 in PTP1B), and mutations of the general acid donor of the WPD loop (Asp181 in PTP1B) also render D2 domains catalytically inert. However, D2 domains in an increasing number of pseudophosphatases appear to have retained their capacity to bind substrates, potentially acting as important regulators of signaling pathways.

3.2. Class I PTPs: receptor tyrosine-specific phosphatases (RPTPs)

Nearly 20% of human PTPs are predicted to contain a transmembrane domain [34], a figure similar to the fly genome where we have identified 8 RPTPs (~18% of the tyrosine phosphatome), 7 of which are likely to be active enzymes (Fig. 2). The functions of RPTPs were first described in the development of the fly's nervous system where these enzymes are essential for the proper regulation of axon guidance and synapse formation. Mutations in Lar, Ptp69D, Ptp99A, Ptp4E, Ptp10D and Ptp52F affect axon guidance, either alone or in combination as each guidance decision made by embryonic motor axons during outgrowth to their muscle targets requires a specific subset of the neural RPTPs. Highly penetrant defects in the CNS and motor axon guidance are typically observed only when specific combinations of two or more RPTPs are removed. Functionally the RPTPs can be divided into two classes: (a) lethals, which have a clear phenotype upon deletion (Lar, Ptp69D and Ptp52F); and (b) viables, which present no phenotype on their own but synergize with each other and with

mutations in the lethal RPTPs to produce stronger phenotypes (**Ptp99A**, **Ptp10D** and **Ptp4E**). Structurally, 3 RPTPs present tandem PTP domains (**Lar**, **Ptp69D** and **Ptp99A**, where the second domain, D2, is catalytically inactive), and a protein architecture reminiscent of the R1/R6 RPTP subtype. The proposed function of the inactive D2 domain is to serve as a dynamic modulator of the D1 domain, which mechanistically could happen in several ways: (i) through the direct inhibition of the D1 domain by physical hindrance (hinge vs. head-and-toe models) [56]; (ii) by serving as a redox sensor for modulating D1 activity [57]; and (iii) possibly D2 could function as a pseudophosphatase domain that interacts with substrates to prevent them from performing their functions [52]. Five RPTPs in the fly genome (**Ptp4E**, **Ptp10D**, **Ptp52F**, **CG42327** and **IA-2**) harbor a single PTP domain.

3.2.1. Tandem domain RPTPs: *Lar*, *Ptp69D* and *Ptp99A*

Drosophila Lar is the fly ortholog of human and mouse R2B subfamily members *PTPRD*, *PTPRF* and *PTPRS*. Like the human enzymes, *Lar* is strongly expressed in the brain and also in tissues of endodermal origin. **Lar** has a crucial role in regulating synapse growth and maturation at the neuromuscular junction, relying on its ligands *Syndecan* (*Sdc*) and **Dally-like**. *Sdc* is a heparan sulfate proteoglycan that contributes to **Lar** function in motor axon guidance. The overexpression of *Sdc* in muscles produces the same phenotype as the overexpression of *Lar* in neurons, and the genetic deletion of *Lar* suppresses the effect produced by ectopic muscle *Sdc*. In muscles *Sdc* can interact with neuronal **Lar** and binding to *Sdc* increases **Lar's** signaling efficiency [58]. In contrast, the family of extracellular matrix molecules known as chondroitin sulfate proteoglycans (CSPGs) negatively regulate axonal growth by interacting with neuronal **Lar** and inactivating the downstream **Akt** and **RhoA** signals. Mice lacking the *Lar* orthologue do overcome the neurite growth restrictions imposed by CSPGs in neuronal cultures [59]. However, the function of **Lar** in controlling R7 photoreceptor axon targeting in the visual system differs in a number of respects: (i) the extracellular domain of **Lar** is different and might be regulated by other ligands; and (ii) R7 targeting does not require **Lar's** phosphatase activity but relies on that of **Ptp69D**. Although **Lar's** phosphatase activity is not required for R7, **Lar** dimerisation probably leads to the assembly of downstream effectors [60]. Thus, the genetic deletion of *Lar* leads to axon elongation and fasciculation deficiency, a phenotype that is partially mimicked in compounded mouse knock-outs of the *Ptprd* and *Ptprs* genes [61]. In particular, the mouse *Ptprs* knockout promotes axonal regeneration and even increases memory and the plasticity of neural interactions in the brain [62]. Similarly, the *C. elegans* ortholog, *ptp-3*, is most highly expressed in the nervous system, from the late embryo to the adult stages [63]. It thus seems that the original function of *Lar* (neuron targeting) has become diversified in the course of evolution into additional functions of brain patterning and synaptic interaction formation in mammals. Not surprisingly, both the mammalian ligand CSPG and the cytoplasmic signaling networks downstream of the receptors have diverged from those of the fly [64,65]. Interestingly, recent work suggests that the inhibition of *Ptprs* might constitute a novel approach in the treatment of spinal cord, brain injuries and neurodegenerative diseases [62,66–69].

The two other tandem domain-containing receptor PTPs, **Ptp69D** and **Ptp99A**, are also involved in neural patterning. Their extracellular domains contain the typical immunoglobulin-like and fibronectin-like domains that mediate cell–cell interactions. In contrast to **Lar**, **Ptp69D** and **Ptp99A** have a much smaller number of fibronectin repeats (3 and 4, respectively). Whereas *Ptp99A* has two detectable orthologues in human (*PTPRG* and *PTPRZ1*), *Ptp69D* is the phylogenetic ortholog of human *CD45* (*PTPRC*), a key regulator of lymphocyte antigen receptor signaling. However, adaptive immune mechanisms are absent in the fly. While being

somewhat functionally redundant, differing expression patterns in the *Drosophila* CNS (*Ptp69D* in young axons, *Ptp99A* and *Lar* in older axons) as well as the study of mutant *Lar*, *Ptp69D* and *Ptp99A*, indicate that these enzymes may have specialized roles in CNS development and in the adult brain of the fly [70]. In embryos lacking *Ptp69D* motor neuron growth cones cease to grow before reaching their muscle targets, or follow incorrect pathways that bypass these muscles. Embryos lacking *Ptp99A* have no distinguishable phenotype, but *Ptp99A Ptp69D* double mutants present a much more severe phenotype. Therefore, *Ptp69D* and *Ptp99A* are required for motor axon guidance and have partially redundant roles during the development of the neuromuscular system [71]. Furthermore, *Ptp69D* seems to function in conjunction with *Ptp10D* in bundle formation and is necessary for axonal growth to the lobes from the peduncle [70], whereas *Lar* mutants display a phenotype of axon overgrowth across the midline of the brain in both larval and adult brains [70]. Given the parallel between neuronal and immune synapses, it is interesting to note that these enzymes have acquired additional roles in immunity in higher animals [72]. For instance the human orthologs of *Ptp99A* possess an extracellular carbonic anhydrase domain (absent in flies), responsible for catalyzing the interconversion of carbon dioxide and bicarbonate to maintain the acid–base balance in blood and tissues. Despite *Ptp69D* and *CD45* (*PTPRC*) being strict phylogenetic orthologs, their proteins' extracellular domains are slightly different, which is understandable since the fly has evolved separately for over 400 million years to possibly recognize different extracellular stimuli while maintaining the same intracellular signaling domain architecture. Finally, the worm ortholog of *Ptp69D* (*clr-1*) has non-neural roles but is also broadly involved in developmental processes as it has been shown to be a negative regulator of the FGF receptor (EGL-15) by dephosphorylation [73].

3.2.2. *Ptp4E*, *Ptp10D* and *Ptp52F*

Ptp4E, **Ptp10D** and **Ptp52F** are all structurally similar with a string of N-terminal fibronectin-like domains and a single, intracellular, active catalytic domain, and all are homologous to enzymes of the R3 subtype (*PTPRB/PTPRO*).

Ptp4E and *Ptp10D* have important roles in neural patterning in the fly, although their expression pattern is not limited to neurons. *Ptp4E* is broadly expressed and its mutants are viable and fertile, but *Ptp4E Ptp10D* double mutants have a mild CNS phenotype and the resulting embryos die before the larval stage. Whereas *Ptp4E Ptp69D* double mutants have no phenotype, *Ptp10D Ptp69D* double mutants present a strong CNS phenotype, where axons cross the midline, and the outer and middle longitudinal bundles are fused to the inner bundle. Therefore both *Ptp10D* and *Ptp69D* are necessary for repulsion of growth cones from the midline of the embryonic CNS [74,75]. *Ptp10D* cooperates with *Lar*, *Ptp69D* and *Ptp99A* to facilitate the outgrowth and bifurcation of the SNa nerve (one of the five main nerve branches), but acts in opposition to the others in regulating the extension of ISN motor axons past intermediate targets [76]. A GAL4-based screening method developed by the Zinn laboratory to identify orphan receptor ligands identified **Stranded at second** (**Sas**) as a **Ptp10D** ligand required to prevent longitudinal axons from crossing the midline. Whereas *sas* is expressed both in neurons and glia, *Ptp10D* expression is restricted to CNS axons [77]. Moreover, in the adult brain, signaling through **Ptp10D** is required for long-term memory but not for learning, early memory or anesthesia-resistant memory [78].

Studies on compound mutations of both *Ptp4E* and *Ptp10D* by Jeon and Zinn unveiled a complementary role in embryonic tracheal tube formation, which is partly controlled by **Ptp4E** and **Ptp10D** through the down-regulation of the FGFR ortholog (**Btl**), **Breathless** and **Pvr** receptor tyrosine kinases (which in turn have

compensatory activities) [79,80]. This non-neuronal function is in line with other reports on murine members of the R3 subtype, such as PTPRJ, which also controls receptor tyrosine kinase activity during organ development [81,82]. The *C. elegans* ortholog of *Ptp10D* (*dep-1*) functions through a similar mechanism by negatively regulating EGFR signaling, but instead controls vulval fate during development, and duct cell and excretory pore development [83].

Ptp52F is selectively expressed in the CNS of late embryos, where *Ptp52F* mRNA knockdown mutants present motor axon and CNS axon guidance phenotypes. However, this phenotype is suppressed in *Lar Ptp52F* double mutants, indicating that these RPTPs compete in the regulation of CNS axon guidance decisions [84]. An associated cell surface receptor, **Tartan**, displays a similar phenotype upon interference and it has been proposed to be a ligand of **Ptp52F** [85]. The expression pattern of *Ptp52F* is very similar to that of its mouse ortholog, Ptpro (also known as stomach-associated phosphatase or SAP-1) [86]. Therefore, in common with their mouse orthologs, this set of fly RPTPs have functional roles that extend beyond the nervous system, and are clearly complementing each other in controlling phosphotyrosine-based signaling pathways involved in pattern formation and cell-to-cell interactions.

Furthermore, RNAi-based strategies have shown that *Ptp52F* plays an indispensable role in the destruction of the larval midgut during the larva-to-pupa transition [86]. The destruction of the larval midgut is a critical developmental process triggered by the molting hormone ecdysone. Ecdysone induces the expression of *Ptp52F*, which in turn dephosphorylates Transitional ER ATPase (**Ter94**), a regulator of the ubiquitin proteasome system. Dephosphorylated **Ter94** leads to the fast degradation of ubiquitinated proteins, including the *Drosophila* inhibitor of apoptosis 1 (**Diap1**) whose degradation is essential for the onset of apoptosis and the initiation of autophagy [87].

3.2.3. CG42327

Almost nothing is known about the RPTP **CG42327** since no mutants have so far been characterized. The *CG42327* gene achieves expression peaks 12–24 h post-fertilisation, during the late larval stages and at various stages throughout the pupal period. In the adult fly *CG42327* is particularly highly expressed in the heart, as well as the eye, the thoracic-abdominal ganglion, the midgut and the larval/adult hindgut and carcass [36].

3.2.4. IA-2

The eighth RPTP, Islet antigen-2 (*IA-2*) is the ortholog of the mammalian genes insulinoma-associated antigen (*PTPRN* and *PTPRN2*), initially described upon detection of high levels of anti-*IA-2* antibodies in type I diabetes patients. Moreover, sera from type I diabetic patients has been reported to recognize *Drosophila IA-2*. *Drosophila IA-2* is predicted to be catalytically inactive due to the lack of the catalytic cysteine (mutated to a glycine residue), and the replacement of the essential aspartate by an alanine residue. In situ hybridization showed that *ia-2* is expressed in the CNS (the neuronal pattern of expression being similar to that of mammals), and the midgut region where it plays an important role in gut development during metamorphosis [88]. Given the evolutionary conservation of *ia-2* genes in *Drosophila* and *C. elegans* (*ida-1*), both of which lack a pancreas and an adaptive immune system, this suggests that essential functions of this pseudophosphatase remain to be discovered.

3.3. Class I PTPs: non-receptor tyrosine-specific phosphatases

Eight non-receptor PTPs are found in the fly genome, which map to 7 of the 10 human subtypes.

3.3.1. CG7180

CG7180 is a PTP gene that we describe here in detail for the first time: **CG7180** harbors 2 PTP domains (thus resembling an RPTP) but lacks any signal peptide or transmembrane segments, and it is expressed in the late pupal stages, in the central nervous system of the adult, as well as in other tissues of endodermal origin. Interestingly only a single transcript encoding 2 exons is reported, with the 5'-terminal exon encoding the entire protein. This is important, as RPTPs are known to have multiple splice isoforms, some of which encode only cytoplasmic PTP domains. Therefore it appears that *CG7180* has a unique evolutionary history by encoding a dual catalytic intracellular PTP. Therefore all evidence points to **CG7180** being a cytoplasmic enzyme. Although no clear orthology relationships can be ascribed to *CG7180*, it bears considerable similarity to a number of receptor PTPs of the R2A subtype (*PTPRK*, *PTPRM*, *PTPRT* and *PTPRU*). Sequence similarity is found throughout the first and second PTP domains, and even in the junction sequence linking them. Two possible hypotheses are that either the *CG7180* gene lost its extracellular domain secondarily, or that such an extracellular domain was never gained. In the light of the work by Muller et al. [89], the latter possibility is more plausible. Upon cloning RPTPs in the sponge *Geodia cydonium* (sponges being examples of primitive metazoans as they lack true tissues or organs, and present no body symmetry), Muller and colleagues proposed that the fibronectin-containing extracellular domain of receptor PTPs, and each of their two PTP domains, evolved independently. The PTP domain would have appeared before the lineage leading to yeasts, but the extracellular fibronectin domain likely appeared immediately prior to the emergence of metazoans. *CG7180* thus presents an exciting opportunity to study the evolution of receptor PTPs with tandem catalytic domains. Examination of the amino acid sequence of the two catalytic domains suggests that the D2 domain is catalytically inactive (as with other D2 domains, the conserved tyrosine residue-Y46 in PTP1B-present in Motif 1 of the NXXKNRY motif is mutated to an Aspartate (NREKNRD)). Additionally, the WPD loop motif of the second domain harbors a methionine instead of the general acid donor aspartate. Moreover, motif 1 of the D1 domain of **CG7180** harbors the sequence NLEKNQN, where the important RY amino acid pair is missing. Besides, in the WPD loop of D1, a WYS motif is found with the proline and the crucial aspartate missing. Therefore, **CG7180** is the first identified cytoplasmic enzyme harboring 2 pseudophosphatase domains.

3.3.2. Corkscrew

Corkscrew (*csw*) is the fly ortholog of the SH2 domain-containing PTPs *SHP-1* (*PTPN6*) and *SHP-2* (*PTPN11*). The structural and functional characteristics of **Corkscrew** have been extremely well conserved in evolution: for instance, the *csw* mutant phenotype mimicks gain-of-function mutations typical of the LEOPARD syndrome (an autosomal dominant Ras/MAPK multisystem condition caused by mutations in *PTPN11*) [90]. Both *SHP-1* and *SHP-2* play critical roles in hematopoiesis as positive and negative regulators, respectively [91]. Moreover, *corkscrew* is involved in oogenesis and is a player in terminal cell fate determination [92], a function mirrored by the *C. elegans* ortholog *ptp-2* [93].

3.3.3. l(1)G0232

The *Drosophila l(1)G0232* gene is orthologous to mammalian *PTPN9* (also known as *PTP-MEG2*). Eight splice isoforms of *l(1)G0232* mRNA have been reported in the fly (compared to six in human), all of which encode an active PTP domain plus 1 or 2 CRAL-TRIO domains, except for the shorter isoforms which only harbor the PTP domain. CRAL-TRIO are ~170 amino acid domains

that form hydrophobic lipid-binding pockets and are generally present in membrane-associated proteins such as GTPases. Although *I(1)G0232* has not been thoroughly studied, mammalian PTP-MEG2 has been reportedly associated with secretory vesicles through its Sec14p domain [94]. Several studies have implicated PTPN9 in the negative regulation of signaling downstream of important tyrosine kinase receptors, such as VEGFR in endothelial cells [95], and ErbB2 and EGFR in breast cancer cell lines [96] by dephosphorylating STAT3 [97]. STAT3 also appears to be a target of PTPN9 during primitive hematopoiesis in zebrafish [98].

3.3.4. Mop

The *myopic* (*mop*) gene is orthologous to *PTPN23* (*HD-PTP*) in mammals, and the only PTP in the fly genome harboring a BRO protein–protein interaction domain. The BRO domain is found in proteins associated with endosomal trafficking through potential interactions with the Escort III complex. Out of 73 *PTPN23* orthologs examined, all but 6 harbor a conserved serine residue (VHCSSGXG) instead of an alanine residue (VHCSAGXG) in the PTP signature motif; it has been suggested that this Ala to Ser mutation in *PTPN23* may influence the entry and positioning of the substrate in the catalytic pocket [99]. Besides, the D → K mutation in the WPD loop appears to contribute to *Mop*'s lack of observed catalytic activity [100]. Despite the abrogation of its catalytic activity, *Mop* has been reported to act as a tumor suppressor by influencing different signaling pathways, for example through the inhibition of receptor protein kinase signaling during their endocytic internalization [101], and by interacting and regulating the transcription factor *Yorkie* [102]. Human *PTPN23* is increasingly recognized as a tumor suppressor since its knockdown leads to an increased epithelial to mesenchymal transition rate, thus facilitating migration and tumor cell invasion [103].

3.3.5. Ptpmeg and Pez

Early analysis of non-receptor PTP sequences identified three specific subtypes in the human genome, each exemplified by the MEG, PEZ and BAS enzymes [104]. In addition to their active catalytic PTP domain, all three contain an N-terminal FERM domain that is known to anchor proteins onto membrane-associated proteins involved in actin rearrangement and cytoskeleton dynamics. This classification scheme was mainly based on the absence of a PDZ domain in the PEZ enzymes, the presence of one PDZ domain in the MEG subfamily, and of multiple PDZ domains in the BAS subfamily. Such classification was retained in the annotation of the human PTPs by Andersen and colleagues with the subtype names NT5 (MEG), NT6 (PEZ) and NT7 (BAS) [55]. However, Edwards et al. noted that no orthologs of human *BAS* exist in *Drosophila*, a finding that we have confirmed here. Recent work has uncovered an important function for *Drosophila* *Pez* in intestinal stem cells by acting on the Hippo signaling pathway, which controls organ growth by regulating cell proliferation and apoptosis. In vitro studies have shown that the human ortholog (*PTPN14*) is an evolutionarily conserved regulator of this pathway [105,106], as well as a regulator of the lymphatic system and choanal development [107]. *PTPN21*, the second human ortholog of *Drosophila* *pez*, controls proliferation [108]. Recently the group of Norbert Perrimon have produced a high-resolution interactome of the Hippo pathway by using existing components of the pathway as TAP-tagged baits, analysed by mass spectrometry [109].

Ptpmeg is involved in neuronal circuit formation in the central brain of the fly, regulating both the establishment and stabilization of axonal projection patterns, and its vertebrate orthologs (*PTPN3* and *PTPN4*) are expressed in the nervous system too [110]. The human orthologs of *Ptpmeg* (*PTPN3* and *PTPN4*) are also negative regulators of T-cell receptor (TCR) signaling (a function absent in the fly), both dephosphorylating the TCR ζ chain [111].

Additionally, *PTPN4* is anti-apoptotic, as was shown by its promotion of the survival of glioblastoma cells, and has been proposed as a therapeutic target [112].

3.3.6. Ptp61F

Ptp61F is the fly ortholog of mammalian *PTPN1* (PTP1B) [113] and *PTPN2* (TC-PTP) [114], and plays fundamental roles in growth, life span and fecundity [115]. Structurally, **Ptp61F** contains a PTP catalytic domain, 2 proline-rich motifs (PXPXXX) and, depending on the splice isoform, a C-terminus with either a nuclear-targeting motif (isoform *Ptp61Fn*), or with a hydrophobic stretch that localizes **Ptp61F** to the cytoplasm (isoform *Ptp61Fm*) [116]. Interestingly, the multiple functions attributed to *Ptp61F* relate to many of the composite functions of mammalian *PTPN1* and *PTPN2*. For instance, *Ptp61F* has been found to be both a negative modulator of the JAK-STAT pathway in *Drosophila* [117,118] and mouse [119], and an important modulator of insulin signaling through *dock*, the fly ortholog of *NCK* [120]. **Ptp61F** has also been shown to control the organization of F-actin via the regulation of *Kette* [121]. More recently, a negative role for **Ptp61F** has been found in stem cell maintenance, as well as its inhibition by the transcription factor *Ken* [122], and a similar role has been reported for *PTPN2* [123]. The deletion of *Ptp61F* produces a multitude of phenotypes reminiscent of a combination of those of mammalian *PTPN1* and *PTPN2* [124,125].

3.3.7. PTP-ER

PTP-ER is the phylogenetic ortholog of the R7 subtype receptor genes *PTPRR* (*HePTP*, *PTP-SL*) and the non-receptor enzymes *PTPN5* and *PTPN7*. *PTP-ER* mutations have been identified in the fly where they affect the development of the R7 photoreceptor, thus supporting its function in MAP kinase regulation. Moreover, recent work in human has shown that *PTPRR* is an important tumor suppressor in a variety of malignancies, including breast and ovarian cancer. This function is likely associated with its role in the negative regulation of MAP kinase signaling [103,126,127].

3.4. Class I PTPs: dual-specificity phosphatases (DSPs)

The DSPs constitute the largest and most diverse group of PTPs whose defining feature is their ability to dephosphorylate both tyrosine and serine/threonine residues within the same substrate. However, we now know that DSPs target a much larger and diverse set of substrates, including phospho-serine, phospho-threonine and phospho-tyrosine residues, phosphoinositide lipids, RNA 5'-triphosphate, and carbohydrates. Although both classical PTPs and DSPs rely on an essential catalytic cysteine residue located at the base of the catalytic cleft, the catalytic pocket of DSPs is generally broader and shallower than that of classical PTPs, which explains why DSPs can accommodate more than one phosphorylated residue [128]. The 21 DSP genes of *Drosophila* can be classified into the same seven distinct human families (MKP, Atypical, Slingshot, PRL, CDC14, PTEN and Myotubularins), and therefore are a streamlined version of the 61 human DSP genes.

3.4.1. MKPs (mitogen-activated protein kinase phosphatases)

MKP family enzymes are defined by their specific ability to dephosphorylate both the phospho-serine and phospho-tyrosine residues in the activation loop (TxY) of MAP kinases (MAPK), a dual phosphorylation requirement that is essential for the catalytic activation of MAPKs by MAP kinase kinases (MEK). MAPKs are typically part of three-tiered pathways (MAPK/MEK/MEKK) activated by a variety of stimuli (e.g. growth factors, cytokines, mitogens, osmotic stress) to enact a diversity of responses (e.g. gene expression changes, cellular proliferation/differentiation, inflammation and apoptosis). The human genome harbors 14 genes encoding

MAPKs (divided into the ERK, JNK, p38 and NLK sub-families) compared to only 7 in *Drosophila* [2]. The dephosphorylation of both phospho-residues of the MAPK activation loop by MKPs results in the complete abolition of MAPK catalytic activity. However, the partial deactivation of MAPKs can be achieved by dephosphorylating the phosphotyrosine residue of the activation loop of MAPKs by classical PTPs, including PTPN5 (STEP), PTPN7 (HePTP) and PTPRR (PTP-SL) [129]. Interestingly, the *PTPN5/PTPN7/PTPRR* group maps to a single gene in *Drosophila* (CG42327). Therefore, both classical PTPs and DUSPs are essential regulators that functionally overlap to fine-tune the activities of MAPK-dependent signaling pathways.

MKPs have been shown to shape the duration, magnitude and spatial organization of MAPK activities, with some MKPs being specific towards a single MAPK while other MKPs are able to regulate multiple MAPK pathways within the same cell [130]. Whereas 11 MKP genes have been described in human, only two (*Mkp3* and *puckered*) exist in the fly, and thus *Drosophila* might be an ideal system to investigate the mechanisms that endow MKPs with spatiotemporal and quantitative control over MAPK responses and cellular outcomes. *Mkp3* (the fly ortholog of human *DUSP6*, *DUSP7* and *DUSP9*) was originally characterized as a negative feedback regulator of EGFR signaling [131], although today we know that **Mkp3** is one of many such negative regulators of this essential pathway [132]. Physiologically **Mkp3** is a negative modulator of innate immunity in the fly gut, without which a strong immune response to the host gut microflora would occur [133]. The *Mkp3* ortholog *DUSP6* has been shown to play roles in both the promotion and inhibition of apoptosis. The pro-apoptotic function of *DUSP6* was shown in a human colorectal cancer cell line where the authors demonstrated that *DUSP6* acts by dephosphorylating ERK upon activation by P53 [134]. Conversely, expression studies on human thyroid tumor samples point to a role in the promotion of tumorigenesis [135]. Overexpression of human *DUSP7* is observed in leukemias, and a role in maintaining pluripotency has recently been identified in mouse embryonic stem (ES) cells [136–138]. Similarly, *DUSP9* also maintains pluripotency in ES cells [139], and additionally *DUSP9* polymorphisms are associated with type 2 diabetes [140,141]. **Puckered (Puc)** is a negative regulator of JNK [142] and was named after its mutant phenotype in the fly's eye. Its human ortholog, *DUSP10*, is also known as Jun N-terminal kinase phosphatase in human, an important down-regulator of the JNK pathway. *DUSP10* is also indirectly a positive regulator of ERK in a JNK/p38 dependent manner [143]. In inflammation, *DUSP10* inhibits chemokine expression and is downregulated by ASC/PYCARD, a key adaptor protein in the inflammatory response [144].

3.4.2. Atypical DUSPs

Drosophila CG7378, CG10089, CG13197 and CG15528 are atypical DSPs that we describe here for the first time. The human orthologs of CG7378 (*DUSP3*, *DUSP13*, *DUSP26*, *DUSP27* and *DUPD1*) are involved in a multitude of processes from cell cycle regulation to spermatogenesis [145,146]. Therefore ascribing a clear function to CG7378 is not straightforward. CG10089 is the fly ortholog of human *DUSP15* and *DUSP22*. *DUSP15* displays high levels of expression in human testis, as does CG10089 in the adult fly testis [145]. *DUSP22* is expressed in the testis as well as in other many other tissues [145]. Since CG10089 is paralogous to *Mkp*, it might have a similar function in the negative regulation of JNK activity. CG13197, the fly ortholog of human *DUSP11*, is a 5'-triphosphatase that preferentially binds RNA, like its paralog *mRNA-cap* [147,148]. *DUSP11* also binds splicing complexes, its expression is controlled by P53 [149], and may even play a role in inflammatory bowel disease [150].

MAP kinase-specific phosphatase (*Mkp*) is a negative regulator of the JNK pathway [151] and the fly ortholog of *DUSP19*.

DUSP19 has also been shown to regulate JNK signaling by binding the activator MKK7, which in turn binds JNK, thus enabling *DUSP19* to dephosphorylate JNK [145]. It has been suggested that *DUSP19* might act as a scaffold protein given that *DUSP19*-mediated MKK7 inhibition is not dependent on the catalytic activity of *DUSP19* [145]. Aberrant regulation of *DUSP19* may also play a role in malignant pleural mesothelioma as syndecan-1 (a heparin sulfate proteoglycan), which is aberrantly expressed in malignant pleural mesothelioma and regulates proliferation in a highly complex way, is known to negative regulate *DUSP19* expression [152].

MAPK Phosphatase 4 (*MKP-4*), like *puc*, is involved in the inhibition of JNK activity upon Gram-negative peptidoglycan-induced activation, thus being part of the *Drosophila* innate immune system [153]. Overexpression of *MKP-4* has also been shown to negatively regulate ERK and p38 MAPKs in *Drosophila* S2 cells, where *MKP-4* is constitutively expressed [153]. The human ortholog, *DUSP12*, harbors a C-terminal C2H2 zinc finger domain, which plays a role in ribosome biosynthesis and cell cycle regulation [154,155]. The yeast ortholog, *YVH1*, lacks the zinc finger domain like *MKP-4* but is equally involved in the assembly of the 60s ribosomal subunit, glycogen metabolism, gametogenesis and vegetative growth [156,157]. Furthermore, human *DUSP12* overexpression has been reported in chronic myeloid leukemia, and *DUSP12* genetic polymorphisms have been associated with type 2 diabetes [158,159]. Interestingly, the *C. elegans* ortholog, C24F3.2, participates in reproduction and fat storage [160,161]. Therefore, *Drosophila* *MKP-4* might also be involved in ribosome biogenesis, as well as being relevant for the study of type 2 diabetes, and its study might provide additional insights into the versatile human *DUSP12*.

The mRNA-capping phosphatase (**mRNA-cap**) is a highly conserved bi-functional enzyme with N-terminal 5'-triphosphatase catalytic activity and a C-terminal guanylyl transferase function. mRNA-cap recognizes the 5' end of eukaryotic mRNA to add the 7-methylguanosine cap which is essential for translation to occur [162]. The human (*RNGTT*) and *C. elegans* (*cel-1*) mRNA-cap orthologs function similarly to their *Drosophila* counterpart. However, in fungi, the triphosphatase and guanylyltransferase activities are carried out by two separate proteins, Cet1p and Cgt1p respectively, with a study showing that they can be replaced by the single mammalian bi-functional enzyme [163].

PTEN-like phosphatase (*Plip*) dephosphorylates the lipid signaling molecule phosphatidylinositol 5-phosphate [164]. In *Drosophila*, **Plip** is localized to the mitochondria and plays a role in ATP production [165]. Its human ortholog, PTPM1, shows some functional similarities in that PTPM1 is also a mitochondrial phosphatase participating in the regulation of ATP production [164]. However, in humans this enzyme also regulates insulin release [166]. The *C. elegans* ortholog, F28C6.8, is implicated in growth and reproduction based on an RNAi screen that resulted in sterile worms that display a slow growth phenotype [167].

3.4.3. Slingshot phosphatases

Ssh is a cofilin phosphatase of the Slingshot family, with an important role in eye morphogenesis during the assembly of ommatidia (the basic units of the compound insect eye), where it works to inhibit actin polymerization by activating cofilin [168]. In addition to its catalytic domain, **Ssh**, like its human orthologs (SSH1, SSH2 and SSH3), also contains a DEK domain N-terminal to the phosphatase catalytic domain, and C-terminal serine- and glutamine-rich regions. The human orthologs act through similar mechanisms, but they seem to be involved in wound healing by affecting keratinocyte motility [169], and therefore the original function of *ssh* might have diverged in metazoans, but maybe not the regulatory mechanisms as phosphorylation by Protein Kinase D (PKD) has recently been identified as a regulator of both human SSH1 and *Drosophila* **Ssh** [170].

3.4.4. PRLs (phosphatases of regenerating liver)

The Phosphatase of Regenerating Liver (PRL) is an oncogenic PTP family that was first identified in the regenerating rat liver [171]. Members of the PRL family can be prenylated, making it the sole PTP family containing the CAAX C-terminal prenylation motif, which is responsible for targeting PRLs to the cell and inner membranes [172]. This prenylation motif is also conserved in the human and *C. elegans* orthologs. **PRL-1** is the only family member in *Drosophila*, and has been reported in the hearts of adult flies at days 7 and 14 in a recent proteome analysis [173]. The human orthologs of *Drosophila* PRL-1 (*PTP4A1*, *PTP4A2* and *PTP4A3*) have been associated with cancer cell proliferation, metastasis, decreased survival time and poor post-operative outcome [174–177]. The recent characterization of PRL family members (by whole-mount immunostaining and in situ hybridization) during the early embryonic development of *Drosophila*, amphioxus and zebrafish showed that PRLs are uniformly expressed in the developing CNS and thus might be involved in early neural development [178].

3.4.5. CDC14 phosphatases

cdc14 is the fly ortholog of human *CDC14A* and *CDC14B*, which have been implicated in a diversity of cellular processes, including DNA repair, DNA damage checkpoint control, centrosome splitting, chromosome segregation and spindle assembly [179]. In *Drosophila*, **Cdc14** has been reported to play a role in cytokinesis [180], and displays an affinity for proteins that have been phosphorylated by proline-dependent kinases such as CDC2, CDK5, ERK1 and P38 [181]. The catalytic site of **Cdc14** is located at the C-terminus whereas the substrate specificity is determined by an N-terminal recognition pocket [181,182]. The yeast (*CDC14*) and *C. elegans* (*cdc-14*) orthologs also have functions in cell cycle control [183,184].

3.4.6. PTEN phosphatases

The phosphatase and tensin homologue deleted from chromosome ten (PTEN) is one of the most frequently mutated tumor suppressor genes, and 7 splice variant mRNAs and encoded polypeptides of the single *Drosophila* *Pten* gene have been described [185]. Since PTEN is such a powerful tumour suppressor, *Pten* mutants have recently been engineered to derive new *Drosophila* cell lines [186]. PTEN not only targets acidic substrates in proteins, but can also dephosphorylate the lipid second messenger phosphatidylinositol-3,4,5 (PIP3), thereby regulating the PI3K/AKT pathway since PIP3s activate PDK1 by recruitment [187]. The crystal structure of PTEN unveiled an unusually large active site capable of accommodating the sugar head group of PIP3. This would enable PTEN to dephosphorylate the 3-position of the inositol sugar ring to counteract PI3 kinase-dependent signaling [187,188]. Moreover, the phospholipid-binding C-terminal tensin phosphatase C2 domain might work to orientate the N-terminal catalytic domain on the cell membrane, and has been shown to inhibit cell migration in human cell lines in vitro [188,189]. PTEN has many roles in vivo, and both the complete and partial loss of PTEN function promote a diversity of cancers in human and mice. Furthermore, *Pten* has recently been shown to have an essential patterning role during *Drosophila* wing development [190]. Given its central importance to the cell, it is not surprising that *PTEN* is under tight transcriptional, post-transcriptional (by micro-RNAs) and post-translational control (e.g. the lipid phosphatase activity of PTEN is regulated by phosphorylation, oxidation and ubiquitination) [191]. Moreover, the C-terminus contains several phosphorylation sites and a PDZ domain-binding site, adding an additional level of regulatory control regarding protein localization, stability and activity [192].

3.4.7. Myotubularin phosphatases

Myotubularins are lipid phosphatases that act upon phosphatidylinositol 3-phosphate and phosphatidylinositol (3,5)-biphosphate. Besides the catalytic domain, myotubularins are characterized by N-terminal PH-GRAM domains (pleckstrin homology glycosyltransferases, Rab-like GTPase activators and myotubularins), and each mammalian member of the myotubularin family acts on its own subset of lipid molecules and has its own specialized function [193]. Of the seven myotubularins identified in *Drosophila* (compared to 15 genes in human), three are most likely pseudophosphatases [194] (**CG5026**, **CG14411** and **Sbf**, Fig. 2). Despite the important involvement of myotubularins in a multitude of human diseases, only three have been studied in detail (**EDTP**, **Mtm** and **Sbf**) [195]. **EDTP** was first identified in the egg of the flesh fly *Sarcophaga peregrina* and subsequently found to play multiple roles starting from oogenesis until early embryogenesis in the fly [196,197]. The mammalian ortholog of **EDTP** (*MTMR14*) is devoid of protein domains accessory to the catalytic domain (like **EDTP**), and is highly expressed in muscle tissue and implicated in the regulation of autophagy [195,198]. *MTMR14* mutations have been linked to centronuclear myopathy [199]. **Mtm** and **Sbf** play important roles in macrophage cortical remodeling, endolysosomal homeostasis and wound healing, and are mutually dependent on each other, with **Mtm** being recruited and stabilized by the pseudophosphatase **Sbf** [200,201]. Similarly, human SBF1 interacts with *MTMR2* to modulate its activity [202]. *Drosophila* *mtm* has three human orthologs (*MTM1*, *MTMR1* and *MTMR2*), which are believed to have undergone neofunctionalization events. For instance, *MTMR2* is a regulator of late endocytosis, whereas *MTM1* is more important in the early endosome [193,203,204]. Myotubularins display a propensity for dimerization. In mammals the orthologs of *Drosophila* (pseudophosphatase) myotubularins **CG5026** (*MTMR9*) and **CG14411** (*MTMR12*) have also been shown to bind catalytically active myotubularin family members indicating that these proteins likely function as adaptors [193]. Perhaps **CG5026** and **CG14411** also interact with catalytically active myotubularins, functioning as adaptors in a manner similar to **Sbf**. *CG3530* is the fly ortholog of human *MTMR6*, *MTMR7* and *MTMR8*. *MTMR6* plays a role in apoptosis and in immunity by negatively regulating CD4⁺ T cell activation by inhibiting KCA3.1, a Ca²⁺-activated potassium channel [193,195,205,206]. *MTMR8* is involved in autophagy [207]. *CG3632* is the ortholog of human *MTMR3* and *MTMR4*: unlike other myotubularins, *MTMR3* localizes to the ER and the Golgi [208], whereas *MTMR4* is involved in early endosome sorting and also regulates BMP signaling [209,210].

3.5. Class II PTPs: low molecular weight phosphatases (LMWPs)

First identified in the human liver [211], LMWPs harbor a bi-functional catalytic domain with both tyrosine phosphatase and arsenate reductase activities, and consequently target both phosphotyrosines and aryl phosphates [212,213]. Although yeast and mammals possess a single LMWP enzyme (ACP1) (Fig. 1A), 4 LMWP genes exist in *Drosophila* (*primo-1*, *primo-2*, *CG14297* and *CG31469*), of which only 2 (*primo-1* and *primo-2*) have been reported before (Fig. 2, Supplementary Table 1). Additionally, only two of these four genes are active phosphatases since both **Primo-1** and **CG31469** are pseudophosphatases. The *primo* genes are so named because of their expression in primary pigment cells of the pupal retina [214], although *primo-2* is also highly expressed in the developing gut, head and central nerve cord axons, both in developing and adult flies. *primo-1* is expressed in all developmental stages except early embryos, and both *primo* genes are believed to play crucial roles in *Drosophila* neurogenesis [214]. *CG14297* is highly expressed in




Fig. 3. Graphical summary of the orthology relationships between human and *Drosophila* PTPs. The tree of human PTPs was generated as follows: for each of the human PTP families, the longest peptide of all of the family genes were aligned with T-Coffee [252], and subsequently curated using Jalview [253]. The *protpars* program of the PHYLIP package [254] was used to estimate the phylogenies using the Parsimony method, and the resulting trees were displayed with the *ade4* R library [255].

the testis of the adult male fly, whereas the pseudophosphatase gene *CG31469* has relatively low expression levels throughout the fly's life (although its expression levels peak in the adult midgut and adult male head). All *Drosophila* LMWPs (*primo-1*, *primo-2*, *CG14297* and *CG31469*) are orthologous to the ubiquitously expressed human enzyme red cell acid phosphatase gene (*ACP1*). *ACP1* polymorphisms have been associated with hemolytic conditions such as favism and hemolytic anemia, which manifests in systemic lupus erythematosus [215,216]. In one colorectal cancer study, an *ACP1* polymorphism was associated with cancer [217]. Given the divergent functions of the mammalian and *Drosophila* LMWPs, it is reasonable to assume that the functions of the fly enzymes are carried out by other phosphatases in mammals.

3.6. Class III PTPs: CDC25 phosphatases

The CDC25 family is represented in *Drosophila* by the paralogous genes *string* (*stg*) and *twine* (*twe*). *string* plays a role at the start of mitotic events during embryogenesis, oogenesis and

regulates proliferation and stem cell maintenance, whereas *twine* plays a role in meiosis and oogenesis [218–222]. Furthermore, the degradation of the **Twine** protein as triggered by the onset of zygotic transcription has recently been found to be a critical switch that allows embryos to progress from the mid-blastula transition stage onto gastrulation. At this stage the cell cycle is remodeled from a short S phase and mitosis to the introduction of a longer S phase and a G2 phase [223]. Accordingly, the human orthologs *CDC25A*, *CDC25B* and *CDC25C* also play critical roles in mitosis [224], and their involvement in cancers has been demonstrated through their association with angiogenesis, invasion and survival time [225–228]. *Saccharomyces cerevisiae* harbors only one CDC25 ortholog (called *MIH1*), whose expression fluctuates during the cell cycle, and also plays an essential role in the initiation of mitosis [229] (N.B. it must be clarified that another yeast gene, also called CDC25, encodes a GNEF for Ras). Interestingly, the rescue of yeast CDC25 mutants can be accomplished by wild-type human CDC25, indicating a strong functional conservation in evolution from yeast to man [230]. Furthermore, in human there is evidence of

specialization within this subfamily: CDC25A has been shown to play a role in the G1/S transition, with CDC25A-blocked cells arresting in G1 [230,231]. Moreover CDC25A and CDC25B cooperatively regulate G2/M, with CDC25B being essential for the initiation of mitosis [232]. Expression of CDC25C is seen in all phases of the cell cycle [232]. Given the complexity of multicellular organisms, such specialization may provide additional checkpoints to maintain synchrony in cell division, with the different genes potentially complementing each other.

3.7. Aspartic acid-based phosphatases: Eye-Absent homologues (Eya)

Eyes-Absent Phosphatases (Eya) are haloacid dehalogenases that require a metal for catalytic activity and use aspartic acid as a nucleophile instead of the classic cysteine residue. *Drosophila Eya* is involved in numerous processes including the regulation of the anti-DNA immune response, retinal determination, spermatocyte development and oogenesis [233–238]. The human Eya phosphatases (EYA1, EYA2, EYA3 and EYA4) play crucial developmental roles in the eye, muscle and ear [239], and similar regulatory networks have been identified in *Drosophila*. For instance, the **Pax-Six-Eya-Dach** network is well-characterized in humans, and orthologs of these proteins exist in the fly [239]. Human Eya phosphatases can shift from the cytoplasm to the nucleus to regulate post-translational modifications through histone dephosphorylation [240], but *Drosophila Eya* appears to be cytoplasmic only [239]. The *C. elegans* ortholog (*EYA-1*) has been implicated in the regulation of apoptosis and embryogenesis, as well as in mesoderm determination into either striated muscle or a coelomocyte fate [241]. Worm *EYA-1* is regulated by factors also present in the fly and human genomes [241].

4. Conclusions and future perspectives

Despite recent efforts on the characterization of the human tyrosine phosphatome [3,34], we lack detailed descriptions of the phosphatomes of simpler but equally relevant model organisms. The genome of *D. melanogaster* encodes 44 PTP genes, representing a streamlined version of the human tyrosine phosphatome. None of the fruit fly PTPs is lineage-specific and all genes have orthologs in human. Conversely, over 70% (78/109) of human PTPs have an ortholog in the fruit fly. Most importantly, fly and human PTPs share a high degree of functional conservation despite millions of years of independent evolution. *Drosophila* harbors enzymes of the same PTP families found in human: Transmembrane Classical PTPs (including all eight subtypes except R4), Non-Receptor PTPs (including all ten subtypes except NT4, NT7 and NT8), Dual-Specificity Phosphatases (MKP, Atypical, Slingshot, PRL, CDC14, PTEN, Myotubularin), Class II Cys-based PTPs (LMWP), Class III Cys-based PTPs (CDC25) and Asp-based PTPs (Eya). Of the fly PTP genes, 12 and 13 are in 1:1 and 1:2 orthology relationships with both mouse and human (i.e. 25/44 PTPs, or ~57%); 15 additional PTPs are in a 1:-many relationship, and four are in a many:1 relationship. Moreover, five yeast PTPs and 30 worm PTPs have homologs in the fly, as well as in mouse and human (Supplementary Table 1).

Our analysis of the functional similarities and divergences, and orthology relationships between the PTPs of the fly and those of other model organisms suggests that *Drosophila* is an ideal modern organism for the study of mammalian PTPs. *Drosophila*'s streamlined tyrosine phosphatome should be more straightforward to study than those of mouse or human (where many PTP knockouts display mild effects, suggesting compensatory mechanisms), as it is much easier to generate compound knockout models in the fly. Over 75% of human disease-associated genes have a homolog in the fly [32], and this figure also holds true for human

PTP-associated diseases [3]. Since the publication of the fly genome, *Drosophila* has emerged as a very successful model for a number of human diseases, including cancer, immunological, developmental and neurodegenerative disorders [242], as well as cardiac conditions [8].

Zebrafish has been favoured by a number of groups for the study of PTPs as this model fish shares many fundamental processes with human [243] and has the great advantage of producing transparent embryos (whose development can be followed by time-lapse microscopy). A fundamental disadvantage of zebrafish is that, although homologs of most human PTPs are found in the fish genome, the whole-genome duplication event that occurred in the teleost lineage ca. 320 million years ago resulted in a large number of duplicated PTP genes [244,245]. The implication is that compound knockouts and complicated analyses will be necessary to dissect sub-functionalization and neo-functionalization events, as well as compensatory mechanisms. Another popular model organism, the sea urchin, is a marine invertebrate widely used in marine, developmental, gene regulation and evolutionary biology studies [246]. Its PTP complement ($n = 66$ genes) is 50% larger than that of the fly, with substantial lineage-specific expansions unrelated to human enzymes [247], and thus is not as ideal as the fly for investigating human tyrosine phosphatases (see Fig. 3).

In the last 15 years protein kinases have arguably become the most popular class of drug targets for the pharmaceutical industry, not only because of their essential roles in regulating cellular processes but also because their druggability principles are well understood [248]. The old concept that the role of phosphatases is to counteract kinases in linear signaling pathways has become superseded by the emerging view that phosphatases play a dominant role in the dynamics of phosphorylation networks by introducing a multitude of negative and positive controls, which in turn control the amplitude and duration of the signal, thus influencing different sets of target genes [6]. Despite the recognition of the importance of PTPs in disease and the dominant effect of phosphatases over kinases, the development of PTP inhibitors has been hindered because PTPs are extremely difficult to drug with small molecules given their close structural relationship and the general hydrophilicity of the compounds identified by large pharmacological screens. The failures of the brute-force approach of high-throughput screening (HTS) for identifying small molecule inhibitors are well known since most hits thus identified cannot be used in vivo as they typically fall short of exhibiting all the desirable characteristics (i.e. low toxicity, absorption, metabolism, distribution and excretion). In this context, the degree of conserved biology and physiology between flies and humans makes *Drosophila* an invaluable model system to overcome some of the technical difficulties associated with the development of PTP inhibitors in disease models. Since *Drosophila* has high face validity with respect to human physiology and disease, primary drug screening could be performed directly in live flies to select high-quality hits that display desirable features such as bioavailability, metabolic stability and low toxicity [8]. This approach will enhance the rate of discovery of PTP inhibitors by reducing the time needed to identify a small collection of potentially more effective leads for subsequent validation by traditional HTS methods. This should be used in combination with genome-wide functional screens with cultured cells carrying pathway-specific reporters, which in the past have successfully identified new cellular pathways and drug targets [249]. Ultimately the chemical inhibition of phosphatases must be understood in terms of phosphatase-substrate networks to gain a systems-level understanding of the effect of specific inhibitors; in this context the group of Maja Köhn have applied a computational approach (by integrating information on phosphatases and their substrates, crystal structures, co-localization and co-

expression data) to derive protein phosphatase–substrate networks on which testable hypotheses can be generated [250]. Despite over 400 million years of independent evolution [251], the tiny fruit fly once again comes to the rescue of biochemists, geneticists and systems biologists to help us understand the essential roles of PTPs in controlling cellular networks and how these can be manipulated for therapeutic purposes.

Acknowledgements

We are very grateful to Drs. Talila Volk (Weizmann Institute) and Acaimo González-Reyes (CABD, Spain) for their critical reading of the manuscript. We also thank Mr. Shaq Liu for excellent systems support and Ms. Mineko Tanimoto for secretarial assistance. TH is a holder of the Samuel Lupovitch Graduate Excellence Fellowship. This work was supported by the WPI Immunology Frontier Research Center. MLT holds the Jeanne and Jean-Louis Lévesque Chair in Cancer Research.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.febslet.2015.03.005>.

References

- Miller, W.T. (2012) Tyrosine kinase signaling and the emergence of multicellularity. *Biochim. Biophys. Acta* 1823, 1053–1057.
- Martin, D.M., Miranda-Saavedra, D. and Barton, G.J. (2009) Kinomer v. 1.0: a database of systematically classified eukaryotic protein kinases. *Nucleic Acids Res.* 37, D244–D250.
- Hatzihristidis, T., Liu, S., Pryszyk, L., Hutchins, A.P., Gabaldon, T., Tremblay, M.L. and Miranda-Saavedra, D. (2013) PTP-central: a comprehensive resource of protein tyrosine phosphatases in eukaryotic genomes. *Methods*.
- Hendriks, W.J., Elson, A., Harroch, S., Pulido, R., Stoker, A. and den Hertog, J. (2013) Protein tyrosine phosphatases in health and disease. *FEBS J.* 280, 708–730.
- Hendriks, W.J., Elson, A., Harroch, S. and Stoker, A.W. (2008) Protein tyrosine phosphatases: functional inferences from mouse models and human diseases. *FEBS J.* 275, 816–830.
- Nguyen, L.K., Matalanas, D., Croucher, D.R., von Kriegsheim, A. and Kholodenko, B.N. (2013) Signalling by protein phosphatases and drug development: a systems-centred view. *FEBS J.* 280, 751–765.
- Rajan, A. and Perrimon, N. (2013) Of flies and men: insights on organismal metabolism from fruit flies. *BMC Biol.* 11, 38.
- Pandey, U.B. and Nichols, C.D. (2011) Human disease models in *Drosophila melanogaster* and the role of the fly in therapeutic drug discovery. *Pharmacol. Rev.* 63, 411–436.
- Ejsmont, R.K. and Hassan, B.A. (2014) The little fly that could: wizardry and artistry of *Drosophila* genomics. *Genes (Basel)* 5, 385–414.
- McGinnis, W. and Krumlauf, R. (1992) Homeobox genes and axial patterning. *Cell* 68, 283–302.
- Artavanis-Tsakonas, S., Rand, M.D. and Lake, R.J. (1999) Notch signaling: cell fate control and signal integration in development. *Science* 284, 770–776.
- Morgan, T.H. (1917) The theory of the gene. *Am. Nat.* 51, 513–544.
- Morgan, T.H. (1928) The Theory of the Gene, Yale University Press. pp. 77–81.
- Wharton, K.A., Johansen, K.M., Xu, T. and Artavanis-Tsakonas, S. (1985) Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. *Cell* 43, 567–581.
- Gaiano, N. and Fishell, G. (2002) The role of notch in promoting glial and neural stem cell fates. *Annu. Rev. Neurosci.* 25, 471–490.
- Aguirre, A., Rubio, M.E. and Gallo, V. (2010) Notch and EGFR pathway interaction regulates neural stem cell number and self-renewal. *Nature* 467, 323–327.
- Hitoshi, S. et al. (2002) Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. *Genes Dev.* 16, 846–858.
- Liu, Z.J. et al. (2003) Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. *Mol. Cell Biol.* 23, 14–25.
- Grego-Bessa, J. et al. (2007) Notch signaling is essential for ventricular chamber development. *Dev. Cell* 12, 415–429.
- Nobta, M., Tsukazaki, T., Shibata, Y., Xin, C., Moriishi, T., Sakano, S., Shindo, H. and Yamaguchi, A. (2005) Critical regulation of bone morphogenetic protein-induced osteoblastic differentiation by Delta1/Jagged1-activated Notch1 signaling. *J. Biol. Chem.* 280, 15842–15848.
- Bolos, V., Grego-Bessa, J. and de la Pompa, J.L. (2007) Notch signaling in development and cancer. *Endocr. Rev.* 28, 339–363.
- Bolos, V., Blanco, M., Medina, V., Aparicio, G., Diaz-Prado, S. and Grande, E. (2009) Notch signalling in cancer stem cells. *Clin. Transl. Oncol.* 11, 11–19.
- Fortini, M.E., Simon, M.A. and Rubin, G.M. (1992) Signalling by the sevenless protein tyrosine kinase is mimicked by Ras1 activation. *Nature* 355, 559–561.
- Nusse, R. and Varmus, H. (2012) Three decades of Wnts: a personal perspective on how a scientific field developed. *EMBO J.* 31, 2670–2684.
- Nusse, R., van Ooyen, A., Cox, D., Fung, Y.K. and Varmus, H. (1984) Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. *Nature* 307, 131–136.
- Rijsewijk, F., Schuermann, M., Wagenaar, E., Parren, P., Weigel, D. and Nusse, R. (1987) The *Drosophila* homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. *Cell* 50, 649–657.
- Morata, G. and Lawrence, P.A. (1977) The development of wingless, a homeotic mutation of *Drosophila*. *Dev. Biol.* 56, 227–240.
- Bellen, H.J. et al. (2004) The BDGP gene disruption project: single transposon insertions associated with 40% of *Drosophila* genes. *Genetics* 167, 761–781.
- Venken, K.J. and Bellen, H.J. (2007) Transgenesis upgrades for *Drosophila melanogaster*. *Development* 134, 3571–3584.
- Adams, M.D. et al. (2000) The genome sequence of *Drosophila melanogaster*. *Science* 287, 2185–2195.
- Rajan, A. and Perrimon, N. (2012) *Drosophila* cytokine unpaired 2 regulates physiological homeostasis by remotely controlling insulin secretion. *Cell* 151, 123–137.
- Reiter, L.T., Potocki, L., Chien, S., Gribskov, M. and Bier, E. (2001) A systematic analysis of human disease-associated gene sequences in *Drosophila melanogaster*. *Genome Res.* 11, 1114–1125.
- Bier, E. (2005) *Drosophila*, the golden bug, emerges as a tool for human genetics. *Nat. Rev. Genet.* 6, 9–23.
- Alonso, A. et al. (2004) Protein tyrosine phosphatases in the human genome. *Cell* 117, 699–711.
- Chao, J.D., Wong, D. and Av-Gay, Y. (2014) Microbial protein-tyrosine kinases. *J. Biol. Chem.* 289, 9463–9472.
- Tweedie, S. et al. (2009) FlyBase: enhancing *Drosophila* gene ontology annotations. *Nucleic Acids Res.* 37, D555–D559.
- Andersen, J.N., Del Vecchio, R.L., Kannan, N., Gergel, J., Neuwald, A.F. and Tonks, N.K. (2005) Computational analysis of protein tyrosine phosphatases: practical guide to bioinformatics and data resources. *Methods* 35, 90–114.
- Morrison, D.K., Murakami, M.S. and Cleghon, V. (2000) Protein kinases and phosphatases in the *Drosophila* genome. *J. Cell Biol.* 150, F57–F62.
- Altschul, S.F., Gish, W., Miller, W., Myers, E.W. and Lipman, D.J. (1990) Basic local alignment search tool. *J. Mol. Biol.* 215, 403–410.
- Miranda-Saavedra, D. and Barton, G.J. (2007) Classification and functional annotation of eukaryotic protein kinases. *Proteins* 68, 893–914.
- Hutchins, A.P., Liu, S., Diez, D. and Miranda-Saavedra, D. (2013) The repertoires of ubiquitinating and deubiquitinating enzymes in eukaryotic genomes. *Mol. Biol. Evol.* 30, 1172–1187.
- Pryszyk, L.P., Huerta-Cepas, J. and Gabaldon, T. (2011) MetaPhOrs: orthology and paralogy predictions from multiple phylogenetic evidence using a consistency-based confidence score. *Nucleic Acids Res.* 39, e32.
- Huerta-Cepas, J., Capella-Gutiérrez, S., Pryszyk, L.P., Marcet-Houben, M. and Gabaldon, T. (2014) PhylomeDB v4: zooming into the plurality of evolutionary histories of a genome. *Nucleic Acids Res.* 42, D897–D902.
- Flicek, P. et al. (2014) Ensembl 2014. *Nucleic Acids Res.* 42, D749–D755.
- Powell, S. et al. (2014) EggNOG v4.0: nested orthology inference across 3686 organisms. *Nucleic Acids Res.* 42, D231–D239.
- Penel, S., Arigon, A.M., Dufayard, J.F., Sertier, A.S., Daubin, V., Duret, L., Gouy, M. and Perriere, G. (2009) Databases of homologous gene families for comparative genomics. *BMC Bioinformatics* 10 (Suppl. 6), S3.
- Schreiber, F., Patricio, M., Muffato, M., Pignatelli, M. and Bateman, A. (2014) TreeFam v9: a new website, more species and orthology-on-the-fly. *Nucleic Acids Res.* 42, D922–D925.
- Ghedini, E. et al. (2007) Draft genome of the filarial nematode parasite *Brugia malayi*. *Science* 317, 1756–1760.
- Hutter, H. et al. (2000) Conservation and novelty in the evolution of cell adhesion and extracellular matrix genes. *Science* 287, 989–994.
- Bollen, M., Peti, W., Ragusa, M.J. and Beullens, M. (2010) The extended PP1 toolkit: designed to create specificity. *Trends Biochem. Sci.* 35, 450–458.
- Cheng, K.C., Klancer, R., Singson, A. and Seydoux, G. (2009) Regulation of MBK-2/DYRK by CDK-1 and the pseudophosphatases EGG-4 and EGG-5 during the oocyte-to-embryo transition. *Cell* 139, 560–572.
- Tonks, N.K. (2009) Pseudophosphatases: grab and hold on. *Cell* 139, 464–465.
- Boudeau, J., Miranda-Saavedra, D., Barton, G.J. and Alessi, D.R. (2006) Emerging roles of pseudokinases. *Trends Cell Biol.* 16, 443–452.
- Zeqiraj, E. and van Aalten, D.M. (2010) Pseudokinases-remnants of evolution or key allosteric regulators? *Curr. Opin. Struct. Biol.* 20, 772–781.
- Andersen, J.N. et al. (2001) Structural and evolutionary relationships among protein tyrosine phosphatase domains. *Mol. Cell Biol.* 21, 7117–7136.
- Tremblay, M.L. (2009) The PTP family photo album. *Cell* 136, 213–214.
- Yang, J., Groen, A., Lemeer, S., Jans, A., Slijper, M., Roe, S.M., den Hertog, J. and Barford, D. (2007) Reversible oxidation of the membrane distal domain of receptor PTPalpha is mediated by a cyclic sulfenamide. *Biochemistry* 46, 709–719.

- [58] Fox, A.N. and Zinn, K. (2005) The heparan sulfate proteoglycan syndecan is an *in vivo* ligand for the *Drosophila* LAR receptor tyrosine phosphatase. *Curr. Biol.* 15, 1701–1711.
- [59] Fisher, D. et al. (2011) Leukocyte common antigen-related phosphatase is a functional receptor for chondroitin sulfate proteoglycan axon growth inhibitors. *J. Neurosci.* 31, 14051–14066.
- [60] Hofmeyer, K. and Treisman, J.E. (2009) The receptor protein tyrosine phosphatase LAR promotes R7 photoreceptor axon targeting by a phosphatase-independent signaling mechanism. *Proc. Natl. Acad. Sci. U.S.A.* 106, 19399–19404.
- [61] Uetani, N., Chagnon, M.J., Kennedy, T.E., Iwakura, Y. and Tremblay, M.L. (2006) Mammalian motoneuron axon targeting requires receptor protein tyrosine phosphatases sigma and delta. *J. Neurosci.* 26, 5872–5880.
- [62] Horn, K.E. et al. (2012) Receptor protein tyrosine phosphatase sigma regulates synapse structure, function and plasticity. *J. Neurochem.* 122, 147–161.
- [63] Harrington, R.J., Gutch, M.J., Hengartner, M.O., Tonks, N.K. and Chisholm, A.D. (2002) The *C. elegans* LAR-like receptor tyrosine phosphatase PTP-3 and the VAB-1 Eph receptor tyrosine kinase have partly redundant functions in morphogenesis. *Development* 129, 2141–2153.
- [64] Van Vactor, D., Wall, D.P. and Johnson, K.G. (2006) Heparan sulfate proteoglycans and the emergence of neuronal connectivity. *Curr. Opin. Neurobiol.* 16, 40–51.
- [65] Chagnon, M.J., Uetani, N. and Tremblay, M.L. (2004) Functional significance of the LAR receptor protein tyrosine phosphatase family in development and diseases. *Biochem. Cell Biol.* 82, 664–675.
- [66] Brown, J.M. et al. (2012) A sulfated carbohydrate epitope inhibits axon regeneration after injury. *Proc. Natl. Acad. Sci. U.S.A.* 109, 4768–4773.
- [67] Fry, E.J., Chagnon, M.J., Lopez-Vales, R., Tremblay, M.L. and David, S. (2010) Corticospinal tract regeneration after spinal cord injury in receptor protein tyrosine phosphatase sigma deficient mice. *Glia* 58, 423–433.
- [68] Duan, Y. and Giger, R.J. (2010) A new role for RPTPsigma in spinal cord injury: signaling chondroitin sulfate proteoglycan inhibition. *Sci Signal* 3, pe6.
- [69] Coles, C.H. et al. (2011) Proteoglycan-specific molecular switch for RPTPsigma clustering and neuronal extension. *Science* 332, 484–488.
- [70] Kurusu, M. and Zinn, K. (2008) Receptor tyrosine phosphatases regulate birth order-dependent axonal fasciculation and midline repulsion during development of the *Drosophila* mushroom body. *Mol. Cell. Neurosci.* 38, 53–65.
- [71] Desai, C.J., Gindhart Jr., J.G., Goldstein, L.S. and Zinn, K. (1996) Receptor tyrosine phosphatases are required for motor axon guidance in the *Drosophila* embryo. *Cell* 84, 599–609.
- [72] Dustin, M.L. (2012) Signaling at neuro/immune synapses. *J. Clin. Invest.* 122, 1149–1155.
- [73] Kokel, M., Borland, C.Z., DeLong, L., Horvitz, H.R. and Stern, M.J. (1998) C1r-1 encodes a receptor tyrosine phosphatase that negatively regulates an FGF receptor signaling pathway in *Caenorhabditis elegans*. *Genes Dev.* 12, 1425–1437.
- [74] Sun, Q., Bahri, S., Schmid, A., Chia, W. and Zinn, K. (2000) Receptor tyrosine phosphatases regulate axon guidance across the midline of the *Drosophila* embryo. *Development* 127, 801–812.
- [75] Jeon, M., Nguyen, H., Bahri, S. and Zinn, K. (2008) Redundancy and compensation in axon guidance: genetic analysis of the *Drosophila* Ptp10D/Ptp4E receptor tyrosine phosphatase subfamily. *Neural Dev.* 3, 3.
- [76] Sun, Q., Schindelholz, B., Knirr, M., Schmid, A. and Zinn, K. (2001) Complex genetic interactions among four receptor tyrosine phosphatases regulate axon guidance in *Drosophila*. *Mol. Cell. Neurosci.* 17, 274–291.
- [77] Lee, H.K., Cording, A., Vielmetter, J. and Zinn, K. (2013) Interactions between a receptor tyrosine phosphatase and a cell surface ligand regulate axon guidance and glial-neuronal communication. *Neuron* 78, 813–826.
- [78] Qian, M., Pan, G., Sun, L., Feng, C., Xie, Z., Tully, T. and Zhong, Y. (2007) Receptor-like tyrosine phosphatase PTP10D is required for long-term memory in *Drosophila*. *J. Neurosci.* 27, 4396–4402.
- [79] Jeon, M., Scott, M.P. and Zinn, K. (2012) Interactions between Type III receptor tyrosine phosphatases and growth factor receptor tyrosine kinases regulate tracheal tube formation in *Drosophila*. *Biol. Open* 1, 548–558.
- [80] Jeon, M. and Zinn, K. (2009) Receptor tyrosine phosphatases control tracheal tube geometries through negative regulation of Egfr signaling. *Development* 136, 3121–3129.
- [81] Palka, H.L., Park, M. and Tonks, N.K. (2003) Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. *J. Biol. Chem.* 278, 5728–5735.
- [82] Trusolino, L., Bertotti, A. and Comoglio, P.M. (2010) MET signalling: principles and functions in development, organ regeneration and cancer. *Nat. Rev. Mol. Cell Biol.* 11, 834–848.
- [83] Berset, T.A., Hoier, E.F. and Hajnal, A. (2005) The *C. elegans* homolog of the mammalian tumor suppressor Dep-1/Sccl1 inhibits EGFR signaling to regulate binary cell fate decisions. *Genes Dev.* 19, 1328–1340.
- [84] Schindelholz, B., Knirr, M., Warrior, R. and Zinn, K. (2001) Regulation of CNS and motor axon guidance in *Drosophila* by the receptor tyrosine phosphatase DPTP52F. *Development* 128, 4371–4382.
- [85] Bugga, L., Ratnaparkhi, A. and Zinn, K. (2009) The cell surface receptor Tartan is a potential *in vivo* substrate for the receptor tyrosine phosphatase Ptp52F. *Mol. Cell. Biol.* 29, 3390–3400.
- [86] Santhanam, A., Liang, S.Y., Chen, D.Y., Chen, G.C. and Meng, T.C. (2012) Midgut-enriched receptor protein tyrosine phosphatase PTP52F is required for *Drosophila* development during larva–pupa transition. *FEBS J.*
- [87] Santhanam, A., Peng, W.H., Yu, Y.T., Sang, T.K., Chen, G.C. and Meng, T.C. (2014) Ecdysone-induced receptor tyrosine phosphatase PTP52F regulates *Drosophila* midgut histolysis by enhancement of autophagy and apoptosis. *Mol. Cell. Biol.* 34, 1594–1606.
- [88] Kim, J., Bang, H., Ko, S., Jung, I., Hong, H. and Kim-Ha, J. (2008) *Drosophila* ia2 modulates secretion of insulin-like peptide. *Comp. Biochem. Physiol. A: Mol. Integr. Physiol.* 151, 180–184.
- [89] Muller, C.I., Blumbach, B., Krasko, A. and Schroder, H.C. (2001) Receptor protein-tyrosine phosphatases: origin of domains (catalytic domain, Ig-related domain, fibronectin type III module) based on the sequence of the sponge *Geodia cydonium*. *Gene* 262, 221–230.
- [90] Oishi, K. et al. (2009) Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during *Drosophila* development. *Hum. Mol. Genet.* 18, 193–201.
- [91] Trop, S., Tremblay, M.L. and Bourdeau, A. (2008) Modulation of bone marrow-derived endothelial progenitor cell activity by protein tyrosine phosphatases. *Trends Cardiovasc. Med.* 18, 180–186.
- [92] Perkins, L.A., Larsen, I. and Perrimon, N. (1992) Corkscrew encodes a putative protein tyrosine phosphatase that functions to transduce the terminal signal from the receptor tyrosine kinase torso. *Cell* 70, 225–236.
- [93] Gutch, M.J., Flint, A.J., Keller, J., Tonks, N.K. and Hengartner, M.O. (1998) The *Caenorhabditis elegans* SH2 domain-containing protein tyrosine phosphatase PTP-2 participates in signal transduction during oogenesis and vulval development. *Genes Dev.* 12, 571–585.
- [94] Saito, K., Williams, S., Bulankina, A., Honing, S. and Mustelin, T. (2007) Association of protein-tyrosine phosphatase MEG2 via its Sec14p homology domain with vesicle-trafficking proteins. *J. Biol. Chem.* 282, 15170–15178.
- [95] Hao, Q., Samten, B., Ji, H.L., Zhao, Z.J. and Tang, H. (2012) Tyrosine phosphatase PTP-MEG2 negatively regulates vascular endothelial growth factor receptor signaling and function in endothelial cells. *Am. J. Physiol. Cell Physiol.* 303, C548–C553.
- [96] Yuan, T., Wang, Y., Zhao, Z.J. and Gu, H. (2010) Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. *J. Biol. Chem.* 285, 14861–14870.
- [97] Su, F. et al. (2012) Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. *Breast Cancer Res.* 14, R38.
- [98] Bu, Y. et al. (2014) Protein tyrosine phosphatase PTPN9 regulates erythroid cell development through STAT3 dephosphorylation in zebrafish. *J. Cell Sci.*
- [99] Gingras, M.C., Zhang, Y.L., Kharitid, D., Barr, A.J., Knapp, S., Tremblay, M.L. and Pause, A. (2009) HD-PTP is a catalytically inactive tyrosine phosphatase due to a conserved divergence in its phosphatase domain. *PLoS One* 4, e5105.
- [100] Chen, D.Y. et al. (2012) The Bro1-domain-containing protein Myopic/HDPTP coordinates with Rab4 to regulate cell adhesion and migration. *J. Cell Sci.* 125, 4841–4852.
- [101] Miura, G.I., Roignant, J.Y., Wassef, M. and Treisman, J.E. (2008) Myopic acts in the endocytic pathway to enhance signaling by the *Drosophila* EGF receptor. *Development* 135, 1913–1922.
- [102] Gilbert, M.M., Tipping, M., Veraksa, A. and Moberg, K.H. (2011) A screen for conditional growth suppressor genes identifies the *Drosophila* homolog of HD-PTP as a regulator of the oncoprotein Yorkie. *Dev. Cell* 20, 700–712.
- [103] Lin, G., Aranda, V., Muthuswamy, S.K. and Tonks, N.K. (2011) Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'. *Genes Dev.* 25, 1412–1425.
- [104] Edwards, K., Davis, T., Marcey, D., Kurihara, J. and Yamamoto, D. (2001) Comparative analysis of the Band 4.1/ezrin-related protein tyrosine phosphatase Pez from two *Drosophila* species: implications for structure and function. *Gene* 275, 195–205.
- [105] Poernbacher, I., Baumgartner, R., Marada, S.K., Edwards, K. and Stocker, H. (2012) *Drosophila* Pez acts in Hippo signaling to restrict intestinal stem cell proliferation. *Curr. Biol.* 22, 389–396.
- [106] Liu, H., Jiang, D., Chi, F. and Zhao, B. (2012) The Hippo pathway regulates stem cell proliferation, self-renewal, and differentiation. *Protein Cell* 3, 291–304.
- [107] Au, A.C., Hernandez, P.A., Lieber, E., Nadroo, A.M., Shen, Y.M., Kelley, K.A., Gelb, B.D. and Diaz, G.A. (2010) Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans. *Am. J. Hum. Genet.* 87, 436–444.
- [108] Carlucci, A. et al. (2008) Protein-tyrosine phosphatase PTPD1 regulates focal adhesion kinase autophosphorylation and cell migration. *J. Biol. Chem.* 283, 10919–10929.
- [109] Kwon, Y., Vinayagam, A., Sun, X., Dephore, N., Gygi, S.P., Hong, P. and Perrimon, N. (2013) The Hippo signaling pathway interactome. *Science* 342, 737–740.
- [110] Whited, J.L., Robichaux, M.B., Yang, J.C. and Garrity, P.A. (2007) Ptpmeg is required for the proper establishment and maintenance of axon projections in the central brain of *Drosophila*. *Development* 134, 43–53.
- [111] Bauler, T.J., Hendriks, W.J. and King, P.D. (2008) The FERM and PDZ domain-containing protein tyrosine phosphatases, PTPN4 and PTPN3, are both dispensable for T cell receptor signal transduction. *PLoS One* 3, e4014.
- [112] Babault, N. et al. (2011) Peptides targeting the PDZ domain of PTPN4 are efficient inducers of glioblastoma cell death. *Structure* 19, 1518–1524.

- [113] Feldhammer, M., Uetani, N., Miranda-Saavedra, D. and Tremblay, M.L. (2013) PTP1B: a simple enzyme for a complex world. *Crit. Rev. Biochem. Mol. Biol.* 48, 430–445.
- [114] Bussieres-Marmen, S., Hutchins, A.P., Schirbel, A., Rebert, N., Tiganis, T., Fiocchi, C., Miranda-Saavedra, D. and Tremblay, M.L. (2013) Characterization of PTPN2 and its use as a biomarker. *Methods*.
- [115] Buszard, B.J., Johnson, T.K., Meng, T.C., Burke, R., Warr, C.G. and Tiganis, T. (2013) The nucleus- and endoplasmic reticulum-targeted forms of protein tyrosine phosphatase 61F regulate *Drosophila* growth, life span, and fecundity. *Mol. Cell. Biol.* 33, 1345–1356.
- [116] Ursuliak, Z., Clemens, J.C., Dixon, J.E. and Price, J.V. (1997) Differential accumulation of DPTP61F alternative transcripts: regulation of a protein tyrosine phosphatase by segmentation genes. *Mech. Dev.* 65, 19–30.
- [117] Baeg, G.H., Zhou, R. and Perrimon, N. (2005) Genome-wide RNAi analysis of JAK/STAT signaling components in *Drosophila*. *Genes Dev.* 19, 1861–1870.
- [118] Muller, P., Kutteneuler, D., Gesellenchen, V., Zeidler, M.P. and Boutros, M. (2005) Identification of JAK/STAT signalling components by genome-wide RNA interference. *Nature* 436, 871–875.
- [119] Pike, K.A., Hutchins, A.P., Vinette, V., Theberge, J.F., Sabbagh, L., Tremblay, M.L. and Miranda-Saavedra, D. (2014) Protein tyrosine phosphatase 1B is a regulator of the interleukin-10-induced transcriptional program in macrophages. *Sci. Signal* 7, ra43.
- [120] Wu, C.L., Buszard, B., Teng, C.H., Chen, W.L., Warr, C.G., Tiganis, T. and Meng, T.C. (2011) Dock/Nck facilitates PTP61F/PTP1B regulation of insulin signalling. *Biochem. J.* 439, 151–159.
- [121] Ku, H.Y., Wu, C.L., Rabinow, L., Chen, G.C. and Meng, T.C. (2009) Organization of F-actin via concerted regulation of Kette by PTP61F and dAbI. *Mol. Cell. Biol.* 29, 3623–3632.
- [122] Issigonis, M. and Matunis, E. (2012) The *Drosophila* BCL6 homolog ken and Barbie promotes somatic stem cell self-renewal in the testis niche. *Dev. Biol.* 368, 181–192.
- [123] Bourdeau, A., Trop, S., Doody, K.M., Dumont, D.J. and Tremblay, M.L. (2013) Inhibition of T cell protein tyrosine phosphatase enhances interleukin-18-dependent hematopoietic stem cell expansion. *Stem Cells* 31, 293–304.
- [124] Bourdeau, A., Dube, N. and Tremblay, M.L. (2005) Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP. *Curr. Opin. Cell Biol.* 17, 203–209.
- [125] Tiganis, T. (2013) PTP1B and TCPTP-nonredundant phosphatases in insulin signaling and glucose homeostasis. *FEBS J.* 280, 445–458.
- [126] Su, P.H. et al. (2012) Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer. *Oncogene*.
- [127] Chirivì, R.G., Noordman, Y.E., Van der Zee, C.E. and Hendriks, W.J. (2007) Altered MAP kinase phosphorylation and impaired motor coordination in PTPRR deficient mice. *J. Neurochem.* 101, 829–840.
- [128] Denu, J.M. and Dixon, J.E. (1998) Protein tyrosine phosphatases: mechanisms of catalysis and regulation. *Curr. Opin. Chem. Biol.* 2, 633–641.
- [129] Tonks, N.K. (2006) Protein tyrosine phosphatases: from genes, to function, to disease. *Nat. Rev. Mol. Cell Biol.* 7, 833–846.
- [130] Caunt, C.J. and Keyse, S.M. (2012) Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. *FEBS J.*
- [131] Kim, S.E., Kim, S.H. and Choi, K.Y. (2003) Regulation of drosophila MKP-3 by drosophila ERK. *Ann. N. Y. Acad. Sci.* 1010, 51–61.
- [132] Butchar, J.P. et al. (2012) New negative feedback regulators of Egfr signaling in *Drosophila*. *Genetics* 191, 1213–1226.
- [133] Leulier, F. and Royet, J. (2009) Maintaining immune homeostasis in fly gut. *Nat. Immunol.* 10, 936–938.
- [134] Piya, S., Kim, J.Y., Bae, J., Seol, D.W., Moon, A.R. and Kim, T.H. (2012) DUSP6 is a novel transcriptional target of p53 and regulates p53-mediated apoptosis by modulating expression levels of Bcl-2 family proteins. *FEBS Lett.* 586, 4233–4240.
- [135] Degl'Innocenti, D. et al. (2012) DUSP6/MKP3 is over-expressed in papillary and poorly-differentiated thyroid carcinoma and contributes to the neoplastic properties of thyroid cancer cells. *Endocr. Relat. Cancer*.
- [136] Levy-Nissenbaum, O., Sagi-Assif, O., Raanani, P., Avigdor, A., Ben-Bassat, I. and Witz, I.P. (2003) Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. *Cancer Lett.* 199, 185–192.
- [137] Levy-Nissenbaum, O. et al. (2003) Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells. *Oncogene* 22, 7649–7660.
- [138] Abujarour, R., Efe, J. and Ding, S. (2010) Genome-wide gain-of-function screen identifies novel regulators of pluripotency. *Stem Cells* 28, 1487–1497.
- [139] Li, Z. et al. (2012) BMP4 signaling acts via dual-specificity phosphatase 9 to control ERK activity in mouse embryonic stem cells. *Cell Stem Cell* 10, 171–182.
- [140] Li, H. et al. (2012) A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes loci in Chinese Hans. *Diabetes*.
- [141] Fukuda, H. et al. (2012) A single nucleotide polymorphism within DUSP9 is associated with susceptibility to type 2 diabetes in a Japanese population. *PLoS One* 7, e46263.
- [142] McEwen, D.G. and Peifer, M. (2005) Puckered, a *Drosophila* MAPK phosphatase, ensures cell viability by antagonizing JNK-induced apoptosis. *Development* 132, 3935–3946.
- [143] Finch, A.R., Caunt, C.J., Perrett, R.M., Tsaneva-Atanasova, K. and McArdle, C.A. (2012) Dual specificity phosphatases 10 and 16 are positive regulators of EGF-stimulated ERK activity: indirect regulation of ERK signals by JNK/p38 selective MAPK phosphatases. *Cell. Signal.* 24, 1002–1011.
- [144] Taxman, D.J. et al. (2011) The NLR adaptor ASC/PYCARD regulates DUSP10, mitogen-activated protein kinase (MAPK), and chemokine induction independent of the inflammasome. *J. Biol. Chem.* 286, 19605–19616.
- [145] Patterson, K.L., Brummer, T., O'Brien, P.M. and Daly, R.J. (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. *Biochem. J.* 418, 475–489.
- [146] Rahmouni, S. et al. (2006) Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. *Nat. Cell Biol.* 8, 524–531.
- [147] Yuan, Y., Li, D.M. and Sun, H. (1998) PIR1, a novel phosphatase that exhibits high affinity to RNA-ribonucleoprotein complexes. *J. Biol. Chem.* 273, 20347–20353.
- [148] Deshpande, T., Takagi, T., Hao, L., Buratowski, S. and Charbonneau, H. (1999) Human PIR1 of the protein-tyrosine phosphatase superfamily has RNA 5'-triphosphatase and diphosphatase activities. *J. Biol. Chem.* 274, 16590–16594.
- [149] Caprara, G., Zamponi, R., Melixetian, M. and Helin, K. (2009) Isolation and characterization of DUSP11, a novel p53 target gene. *J. Cell Mol. Med.* 13, 2158–2170.
- [150] Hasler, R. et al. (2011) Alterations of pre-mRNA splicing in human inflammatory bowel disease. *Eur. J. Cell Biol.* 90, 603–611.
- [151] Kim, Y.I., Ryu, T., Lee, J., Heo, Y.S., Ahnn, J., Lee, S.J. and Yoo, O. (2010) A genetic screen for modifiers of *Drosophila* caspase Dcp-1 reveals caspase involvement in autophagy and novel caspase-related genes. *BMC Cell Biol.* 11, 9.
- [152] Szatmari, T., Mundt, F., Heidari-Hamedani, G., Zong, F., Ferolla, E., Alexeyenko, A., Hjerpe, A. and Dobra, K. (2012) Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells. *PLoS One* 7, e48091.
- [153] Sun, L., Yu, M.C., Kong, L., Zhuang, Z.H., Hu, J.H. and Ge, B.X. (2008) Molecular identification and functional characterization of a *Drosophila* dual-specificity phosphatase DMKP-4 which is involved in PGN-induced activation of the JNK pathway. *Cell. Signal.* 20, 1329–1337.
- [154] Kozarova, A., Hudson, J.W. and Vacratsis, P.O. (2011) The dual-specificity phosphatase hYVH1 (DUSP12) is a novel modulator of cellular DNA content. *Cell Cycle* 10, 1669–1678.
- [155] Muda, M., Manning, E.R., Orth, K. and Dixon, J.E. (1999) Identification of the human YVH1 protein-tyrosine phosphatase orthologue reveals a novel zinc binding domain essential for in vivo function. *J. Biol. Chem.* 274, 23991–23995.
- [156] Kemmler, S., Occhipinti, L., Veisu, M. and Panse, V.G. (2009) Yvh1 is required for a late maturation step in the 60S biogenesis pathway. *J. Cell Biol.* 186, 863–880.
- [157] Beeser, A.E. and Cooper, T.G. (2000) The dual-specificity protein phosphatase Yvh1p regulates sporulation, growth, and glycogen accumulation independently of catalytic activity in *Saccharomyces cerevisiae* via the cyclic AMP-dependent protein kinase cascade. *J. Bacteriol.* 182, 3517–3528.
- [158] Das, S.K. et al. (2006) Polymorphisms in the glucokinase-associated, dual-specificity phosphatase 12 (DUSP12) gene under chromosome 1q21 linkage peak are associated with type 2 diabetes. *Diabetes* 55, 2631–2639.
- [159] Biernacki, M.A. et al. (2010) Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. *Cancer Res.* 70, 906–915.
- [160] Colaiacono, M.P., Stanfield, G.M., Reddy, K.C., Reinke, V., Kim, S.K. and Villeneuve, A.M. (2002) A targeted RNAi screen for genes involved in chromosome morphogenesis and nuclear organization in the *Caenorhabditis elegans* germline. *Genetics* 162, 113–128.
- [161] Ashrafi, K., Chang, F.Y., Watts, J.L., Fraser, A.G., Kamath, R.S., Ahringer, J. and Ruvkun, G. (2003) Genome-wide RNAi analysis of *Caenorhabditis elegans* fat regulatory genes. *Nature* 421, 268–272.
- [162] Cowling, V.H. (2010) Regulation of mRNA cap methylation. *Biochem. J.* 425, 295–302.
- [163] Schwer, B., Lehman, K., Saha, N. and Shuman, S. (2001) Characterization of the mRNA capping apparatus of *Candida albicans*. *J. Biol. Chem.* 276, 1857–1864.
- [164] Pagliarini, D.J., Worby, C.A. and Dixon, J.E. (2004) A PTEN-like phosphatase with a novel substrate specificity. *J. Biol. Chem.* 279, 38590–38596.
- [165] Chang, Y.C., Hung, W.T., Chang, H.C., Wu, C.L., Chiang, A.S., Jackson, G.R. and Sang, T.K. (2011) Pathogenic VCP/TER94 alleles are dominant actives and contribute to neurodegeneration by altering cellular ATP level in a *Drosophila* IBMDF model. *PLoS Genet.* 7, e1001288.
- [166] Pagliarini, D.J., Wiley, S.E., Kimple, M.E., Dixon, J.R., Kelly, P., Worby, C.A., Casey, P.J. and Dixon, J.E. (2005) Involvement of a mitochondrial phosphatase in the regulation of ATP production and insulin secretion in pancreatic beta cells. *Mol. Cell* 19, 197–207.
- [167] Simmer, F. et al. (2003) Genome-wide RNAi of *C. elegans* using the hypersensitive rrf-3 strain reveals novel gene functions. *PLoS Biol.* 1, E12.
- [168] Lin, C.M., Lin, P.Y., Li, Y.C. and Hsu, J.C. (2012) Capulet and Slingshot share overlapping functions during *Drosophila* eye morphogenesis. *J. Biomed. Sci.* 19, 46.
- [169] Kligys, K., Claiborne, J.N., DeBiase, P.J., Hopkinson, S.B., Wu, Y., Mizuno, K. and Jones, J.C. (2007) The slingshot family of phosphatases mediates Rac1 regulation of cofilin phosphorylation, laminin-332 organization, and motility behavior of keratinocytes. *J. Biol. Chem.* 282, 32520–32528.

- [170] Barisic, S., Nagel, A.C., Franz-Wachtel, M., Macek, B., Preiss, A., Link, G., Maier, D. and Hausser, A. (2011) Phosphorylation of Ser 402 impedes phosphatase activity of slingshot 1. *EMBO Rep.* 12, 527–533.
- [171] Mohn, K.L., Laz, T.M., Hsu, J.C., Melby, A.E., Bravo, R. and Taub, R. (1991) The immediate-early growth response in regenerating liver and insulin-stimulated H-35 cells: comparison with serum-stimulated 3T3 cells and identification of 41 novel immediate-early genes. *Mol. Cell. Biol.* 11, 381–390.
- [172] Rios, P., Li, X. and Kohn, M. (2012) Molecular mechanisms of the PRL phosphatases. *FEBS J.*
- [173] Cammarato, A. et al. (2011) A mighty small heart: the cardiac proteome of adult *Drosophila melanogaster*. *PLoS One* 6, e18497.
- [174] Lu, J.W., Chang, J.G., Yeh, K.T., Chen, R.M., Tsai, J.J., Su, W.W. and Hu, R.M. (2012) Increased expression of PRL-1 protein correlates with shortened patient survival in human hepatocellular carcinoma. *Clin. Transl. Oncol.* 14, 287–293.
- [175] Krndjija, D. et al. (2012) The phosphatase of regenerating liver 3 (PRL-3) promotes cell migration through Arf-activity-dependent stimulation of integrin alpha5 recycling. *J. Cell Sci.* 125, 3883–3892.
- [176] Tamagawa, H. et al. (2012) The expression of the phosphatase regenerating liver 3 gene is associated with outcome in patients with colorectal cancer. *Hepatogastroenterology* 59.
- [177] Sun, Z.H. and Bu, P. (2012) Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line. *Exp. Ther. Med.* 3, 1077–1081.
- [178] Lin, M.D. et al. (2013) Expression of phosphatase of regenerating liver family genes during embryogenesis: an evolutionary developmental analysis among *Drosophila*, amphioxus, and zebrafish. *BMC Dev. Biol.* 13, 18.
- [179] Mocciano, A. and Schiebel, E. (2010) Cdc14: a highly conserved family of phosphatases with non-conserved functions? *J. Cell Sci.* 123, 2867–2876.
- [180] Gregory, S.L., Shandala, T., O'Keefe, L., Jones, L., Murray, M.J. and Saint, R. (2007) A *Drosophila* overexpression screen for modifiers of Rho signalling in cytokinesis. *Fly (Austin)* 1, 13–22.
- [181] Gray, C.H. and Barford, D. (2003) Getting in the ring: proline-directed substrate specificity in the cell cycle proteins Cdc14 and CDK2-cyclinA3. *Cell Cycle* 2, 500–502.
- [182] Gray, C.H., Good, V.M., Tonks, N.K. and Barford, D. (2003) The structure of the cell cycle protein Cdc14 reveals a proline-directed protein phosphatase. *EMBO J.* 22, 3524–3535.
- [183] Traverso, E.E., Baskerville, C., Liu, Y., Shou, W., James, P., Deshaies, R.J. and Charbonneau, H. (2001) Characterization of the Net1 cell cycle-dependent regulator of the Cdc14 phosphatase from budding yeast. *J. Biol. Chem.* 276, 21924–21931.
- [184] Roy, S.H., Clayton, J.E., Holmen, J., Beltz, E. and Saito, R.M. (2011) Control of Cdc14 activity coordinates cell cycle and development in *Caenorhabditis elegans*. *Mech. Dev.* 128, 317–326.
- [185] Di Cristofano, A. and Pandolfi, P.P. (2000) The multiple roles of PTEN in tumor suppression. *Cell* 100, 387–390.
- [186] Justiniano, S.E., Mathew, A., Mitra, S., Manivannan, S.N. and Simcox, A. (2012) Loss of the tumor suppressor Pten promotes proliferation of *Drosophila melanogaster* cells in vitro and gives rise to continuous cell lines. *PLoS One* 7, e31417.
- [187] Song, M.S., Salmena, L. and Pandolfi, P.P. (2012) The functions and regulation of the PTEN tumour suppressor. *Nat. Rev. Mol. Cell Biol.* 13, 283–296.
- [188] Lee, J.O. et al. (1999) Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. *Cell* 99, 323–334.
- [189] Raftopoulos, M., Etienne-Manneville, S., Self, A., Nicholls, S. and Hall, A. (2004) Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. *Science* 303, 1179–1181.
- [190] Bardet, P.L. et al. (2013) PTEN controls junction lengthening and stability during cell rearrangement in epithelial tissue. *Dev. Cell* 25, 534–546.
- [191] Leslie, N.R. and Foti, M. (2011) Non-genomic loss of PTEN function in cancer: not in my genes. *Trends Pharmacol. Sci.* 32, 131–140.
- [192] Tonks, N.K. (2012) Protein tyrosine phosphatases: from housekeeping enzymes to master-regulators of signal transduction. *FEBS J.*
- [193] Mruk, D.D. and Cheng, C.Y. (2011) The myotubularin family of lipid phosphatases in disease and in spermatogenesis. *Biochem. J.* 433, 253–262.
- [194] Nandurkar, H.H. et al. (2003) Identification of myotubularin as the lipid phosphatase catalytic subunit associated with the 3-phosphatase adapter protein, 3-PAP. *Proc. Natl. Acad. Sci. U.S.A.* 100, 8660–8665.
- [195] Amoasii, L., Hnia, K. and Laporte, J. (2012) Myotubularin phosphoinositide phosphatases in human diseases. *Curr. Top. Microbiol. Immunol.* 362, 209–233.
- [196] Yamaguchi, S., Katagiri, S., Sekimizu, K., Natori, S. and Homma, K.J. (2005) Involvement of EDTP, an egg-derived tyrosine phosphatase, in the early development of *Drosophila melanogaster*. *J. Biochem.* 138, 721–728.
- [197] Yamaguchi, S., Homma, K. and Natori, S. (1999) A novel egg-derived tyrosine phosphatase, EDTP, that participates in the embryogenesis of *Sarcophaga peregrina* (flesh fly). *Eur. J. Biochem.* 259, 946–953.
- [198] Vergne, I., Roberts, E., Elmaoued, R.A., Tosch, V., Delgado, M.A., Proikas-Cezanne, T., Laporte, J. and Deretic, V. (2009) Control of autophagy initiation by phosphoinositide 3-phosphatase Jumpy. *EMBO J.* 28, 2244–2258.
- [199] Tosch, V. et al. (2006) A novel PtdIns3P and PtdIns(3,5)P2 phosphatase with an inactivating variant in centronuclear myopathy. *Hum. Mol. Genet.* 15, 3098–3106.
- [200] Jean, S., Cox, S., Schmidt, E.J., Robinson, F.L. and Kiger, A. (2012) Sbf/MTMR13 coordinates PI(3)P and Rab21 regulation in endocytic control of cellular remodeling. *Mol. Biol. Cell* 23, 2723–2740.
- [201] Velichkova, M., Juan, J., Kadandale, P., Jean, S., Ribeiro, I., Raman, V., Stefan, C. and Kiger, A.A. (2010) *Drosophila* Mtm and class II PI3K coregulate a PI(3)P pool with cortical and endolysosomal functions. *J. Cell Biol.* 190, 407–425.
- [202] Kim, S.A., Vacratsis, P.O., Firestein, R., Cleary, M.L. and Dixon, J.E. (2003) Regulation of myotubularin-related (MTMR)2 phosphatidylinositol phosphatase by MTMR5, a catalytically inactive phosphatase. *Proc. Natl. Acad. Sci. U.S.A.* 100, 4492–4497.
- [203] Cao, C., Backer, J.M., Laporte, J., Bedrick, E.J. and Wandinger-Ness, A. (2008) Sequential actions of myotubularin lipid phosphatases regulate endosomal PI(3)P and growth factor receptor trafficking. *Mol. Biol. Cell* 19, 3334–3346.
- [204] Chaussade, C. et al. (2003) Expression of myotubularin by an adenoviral vector demonstrates its function as a phosphatidylinositol 3-phosphate [PtdIns(3)P] phosphatase in muscle cell lines: involvement of PtdIns(3)P in insulin-stimulated glucose transport. *Mol. Endocrinol.* 17, 2448–2460.
- [205] Srivastava, S. et al. (2006) Phosphatidylinositol-3 phosphatase myotubularin-related protein 6 negatively regulates CD4 T cells. *Mol. Cell Biol.* 26, 5595–5602.
- [206] Zou, J., Chang, S.C., Marjanovic, J. and Majerus, P.W. (2009) Increases MTMR6 enzyme activity, stability, and role in apoptosis. *J. Biol. Chem.* 284, 2064–2071.
- [207] Zou, J., Chang, C., Marjanovic, J., Kisseleva, M.V., Majerus, P.W. and Wilson, M.P. (2012) Myotubularin-related protein (MTMR) 9 determines the enzymatic activity, substrate specificity, and role in autophagy of MTMR8. *Proc. Natl. Acad. Sci. U.S.A.* 109, 9539–9544.
- [208] Robinson, F.L. and Dixon, J.E. (2006) Myotubularin phosphatases: policing 3-phosphoinositides. *Trends Cell Biol.* 16, 403–412.
- [209] Naughtin, M.J. et al. (2010) The myotubularin phosphatase MTMR4 regulates sorting from early endosomes. *J. Cell Sci.* 123, 3071–3083.
- [210] Yu, J., He, X., Chen, Y.G., Hao, Y., Yang, S., Wang, L., Pan, L. and Tang, H. (2012) Myotubularin-related protein 4 (MTMR4) attenuates BMP/Dpp signaling by dephosphorylation of Smad proteins. *J. Biol. Chem.*
- [211] Rehkopf, D.M. and Etten, R.L. (1975) Human liver acid phosphatases. *Hoppe Seyler's Z. Physiol. Chem.* 356, 1775–1782.
- [212] Wo, Y.Y., McCormack, A.L., Shabanowitz, J., Hunt, D.F., Davis, J.P., Mitchell, G.L. and Van Etten, R.L. (1992) Sequencing, cloning, and expression of human red cell-type acid phosphatase, a cytoplasmic phosphotyrosyl protein phosphatase. *J. Biol. Chem.* 267, 10856–10865.
- [213] Shekels, L.L., Smith, A.J., Van Etten, R.L. and Bernlohr, D.A. (1992) Identification of the adipocyte acid phosphatase as a PAO-sensitive tyrosyl phosphatase. *Protein Sci.* 1, 710–721.
- [214] Miller, D.T., Read, R., Rusconi, J. and Cagan, R.L. (2000) The *Drosophila* primo locus encodes two low-molecular-weight tyrosine phosphatases. *Gene* 243, 1–9.
- [215] Polzonetti, V., Passini, V. and Lucarini, N. (2011) Association between ACP(1) genetic polymorphism and favism. *Genet. Mol. Res.* 10, 878–884.
- [216] Teruel, M. et al. (2012) Novel association of acid phosphatase locus 1* C allele with systemic lupus erythematosus. *Hum. Immunol.* 73, 107–110.
- [217] Gloria-Bottini, F., Spina, C., Nicotra, M., Saccucci, P., Ambrosi, S. and Bottini, E. (2012) Acid phosphatase locus 1 genetic polymorphism and cancer grading. *Am. J. Med. Sci.* 344, 32–34.
- [218] Edgar, B.A. and O'Farrell, P.H. (1989) Genetic control of cell division patterns in the *Drosophila* embryo. *Cell* 57, 177–187.
- [219] Inaba, M., Yuan, H. and Yamashita, Y.M. (2011) String (Cdc25) regulates stem cell maintenance, proliferation and aging in *Drosophila testis*. *Development* 138, 5079–5086.
- [220] Swaminathan, A. and Pile, L.A. (2010) Regulation of cell proliferation and wing development by *Drosophila* SIN3 and String. *Mech. Dev.* 127, 96–106.
- [221] Mukai, M., Kitadate, Y., Arita, K., Shigenobu, S. and Kobayashi, S. (2006) Expression of meiotic genes in the germline progenitors of *Drosophila* embryos. *Gene Expr. Patterns* 6, 256–266.
- [222] Alpey, L., Jimenez, J., White-Cooper, H., Dawson, I., Nurse, P. and Glover, D.M. (1992) Twine, a cdc25 homolog that functions in the male and female germline of *Drosophila*. *Cell* 69, 977–988.
- [223] Farrell, J.A. and O'Farrell, P.H. (2013) Mechanism and regulation of Cdc25/Twine protein destruction in embryonic cell-cycle remodeling. *Curr. Biol.* 23, 118–126.
- [224] Galaktionov, K. and Beach, D. (1991) Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. *Cell* 67, 1181–1194.
- [225] Boldrini, L., Gisfredi, S., Ursino, S., Lucchi, M., Mussi, A. and Fontanini, G. (2007) CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma. *Hum. Pathol.* 38, 1563–1568.
- [226] Brogini, M. et al. (2000) Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. *Anticancer Res.* 20, 4835–4840.
- [227] He, N. et al. (2005) Regulation of lung cancer cell growth and invasiveness by beta-TRCP. *Mol. Carcinog.* 42, 18–28.
- [228] Ito, Y., Yoshida, H., Urano, T., Takamura, Y., Miya, A., Kuma, K. and Miyachi, A. (2004) Expression of cdc25A and cdc25B phosphatase in breast carcinoma. *Breast Cancer* 11, 295–300.

- [229] Russell, P., Moreno, S. and Reed, S.I. (1989) Conservation of mitotic controls in fission and budding yeasts. *Cell* 57, 295–303.
- [230] Jinno, S., Suto, K., Nagata, A., Igarashi, M., Kanaoka, Y., Nojima, H. and Okayama, H. (1994) Cdc25A is a novel phosphatase functioning early in the cell cycle. *EMBO J.* 13, 1549–1556.
- [231] Kiyokawa, H. and Ray, D. (2008) In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets. *Anticancer Agents Med. Chem.* 8, 832–836.
- [232] Lindqvist, A., Kallstrom, H., Lundgren, A., Barsoum, E. and Rosenthal, C.K. (2005) Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1-Cdk1 at the centrosome. *J. Cell Biol.* 171, 35–45.
- [233] Morillo, S.A., Braid, L.R., Verheyen, E.M. and Rebay, I. (2012) Nemo phosphorylates eyes absent and enhances output from the Eya-Sine oculis transcriptional complex during *Drosophila* retinal determination. *Dev. Biol.* 365, 267–276.
- [234] Salzer, C.L., Elias, Y. and Kumar, J.P. (2010) The retinal determination gene eyes absent is regulated by the EGF receptor pathway throughout development in *Drosophila*. *Genetics* 184, 185–197.
- [235] Pignoni, F., Hu, B., Zavitz, K.H., Xiao, J., Garrity, P.A. and Zipursky, S.L. (1997) The eye-specification proteins So and Eya form a complex and regulate multiple steps in *Drosophila* eye development. *Cell* 91, 881–891.
- [236] Fabrizio, J.J., Boyle, M. and DiNardo, S. (2003) A somatic role for eyes absent (*eya*) and sine oculis (*so*) in *Drosophila* spermatocyte development. *Dev. Biol.* 258, 117–128.
- [237] Bemmann, W. and Troger, R. (1975) The influence of hydrocarbon and glucose medium on the fungi strains *Absidia coerulea* (p 23) and *Penicillium spec.* (m 49). I. A comparison of growth in shake and standing culture (author's transl). *Zentralbl Bakteriol Parasitenkd Infektionskr Hyg* 130, 505–512.
- [238] Bonini, N.M., Leiserson, W.M. and Benzer, S. (1993) The eyes absent gene: genetic control of cell survival and differentiation in the developing *Drosophila* eye. *Cell* 72, 379–395.
- [239] Tadjuidje, E. and Hegde, R.S. (2012) The eyes absent proteins in development and disease. *Cell. Mol. Life Sci.*
- [240] Cook, P.J., Ju, B.G., Telese, F., Wang, X., Glass, C.K. and Rosenfeld, M.G. (2009) Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. *Nature* 458, 591–596.
- [241] Amin, N.M., Lim, S.E., Shi, H., Chan, T.L. and Liu, J. (2009) A conserved Six-Eya cassette acts downstream of Wnt signaling to direct non-myogenic versus myogenic fates in the *C. elegans* postembryonic mesoderm. *Dev. Biol.* 331, 350–360.
- [242] Bakhoum, M.F. and Jackson, G.R. (2011) Demise of the flies: why *Drosophila* models still matter. *Prog. Mol. Biol. Transl. Sci.* 100, 483–498.
- [243] Paardekooper Overman, J. and den Hertog, J. (2013) Zebrafish as a model to study PTPs during development. *Methods*.
- [244] Jaillon, O. et al. (2004) Genome duplication in the teleost fish *Tetraodon nigroviridis* reveals the early vertebrate proto-karyotype. *Nature* 431, 946–957.
- [245] Vandepoele, K., De Vos, W., Taylor, J.S., Meyer, A. and Van de Peer, Y. (2004) Major events in the genome evolution of vertebrates: paranome age and size differ considerably between ray-finned fishes and land vertebrates. *Proc. Natl. Acad. Sci. U.S.A.* 101, 1638–1643.
- [246] Sodergren, E. et al. (2006) The genome of the sea urchin *Strongylocentrotus purpuratus*. *Science* 314, 941–952.
- [247] Byrum, C.A., Walton, K.D., Robertson, A.J., Carbonneau, S., Thomason, R.T., Coffman, J.A. and McClay, D.R. (2006) Protein tyrosine and serine-threonine phosphatases in the sea urchin, *Strongylocentrotus purpuratus*: identification and potential functions. *Dev. Biol.* 300, 194–218.
- [248] Cohen, P. and Tcherpakov, M. (2010) Will the ubiquitin system furnish as many drug targets as protein kinases? *Cell* 143, 686–693.
- [249] Mohr, S.E., Smith, J.A., Shamu, C.E., Neumuller, R.A. and Perrimon, N. (2014) RNAi screening comes of age: improved techniques and complementary approaches. *Nat. Rev. Mol. Cell Biol.* 15, 591–600.
- [250] Li, X., Wilmanns, M., Thornton, J. and Kohn, M. (2013) Elucidating human phosphatase-substrate networks. *Sci. Signal* 6, rs10.
- [251] Gaunt, M.W. and Miles, M.A. (2002) An insect molecular clock dates the origin of the insects and accords with palaeontological and biogeographic landmarks. *Mol. Biol. Evol.* 19, 748–761.
- [252] Magis, C., Taly, J.F., Bussotti, G., Chang, J.M., Di Tommaso, P., Erb, I., Espinosa-Carrasco, J. and Notredame, C. (2014) T-coffee: tree-based consistency objective function for alignment evaluation. *Methods Mol. Biol.* 1079, 117–129.
- [253] Waterhouse, A.M., Procter, J.B., Martin, D.M., Clamp, M. and Barton, G.J. (2009) Jalview version 2 – a multiple sequence alignment editor and analysis workbench. *Bioinformatics* 25, 1189–1191.
- [254] Felsenstein, J. (1989) PHYLIP – phylogeny inference package (version 3.2). *Cladistics* 5, 164–166.
- [255] Dray, S. and Dufour, A.B. (2007) The ade4 package: implementing the duality diagram for ecologists. *J. Stat. Softw.* 22, 1–20.